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Abstract 
 
THE ROLE OF TKS5 SH3 DOMAINS IN INVADOPODIA  
DEVELOPMENT AND ACTIVITY 
 
Christina Adele Daly 
B.S., Appalachian State University 
M.S., Appalachian State University 
 
 
Chairperson:  Darren Seals, Ph.D. 
 
 
	 One mechanism by which cancer cells metastasize is through the formation of actin-
rich structures called invadopodia.  Tks5 is a Src tyrosine kinase substrate and scaffolding 
protein necessary for invadopodia formation and associated extracellular matrix-remodeling 
activity.  The purpose of this study is to appreciate how the five, protein binding SH3 
domains of Tks5 impact its function.  SH3 domains are commonly found in 
adaptor/scaffolding proteins where they mediate binding to poly-proline-containing amino 
acid sequences.  Some binding partners for Tks5 have been previously identified, but the 
functional implications for these interactions are not well understood in the context of cancer.  
Here, Tks5 constructs harboring point mutations in a key tryptophan residue involved in SH3 
domain binding activity were introduced into cancer cells to study invadopodia development 
and activity.  In the LNCaP prostate cancer model system, mutant Tks5 constructs exert 
differential effects on extracellular matrix degradation based on a microscopic cell-based 
assay involving the proteolysis of gelatin.  Specifically, mutations in the last two SH3 
domains inhibit gelatin degradation relative to a wild-type Tks5 construct while mutations in 
	v 
the first three SH3 domains accentuate this activity approximately 2.5 to 4.0 fold.  In a 
related study, Myc epitope tagged, mutant Tks5 constructs were introduced into invadopodia-
competent Src-transformed fibroblasts in order to observe their localization by fluorescence 
microscopy.  Wild-type Tks5-Myc readily co-localizes with punctate and ring-shaped, F-
actin-rich invadopodia structures in this cell line, as do Tks5-Myc constructs with mutations 
in either of the last two SH3 domains.  In contrast, Tks5-Myc constructs with mutations in 
any of the first three SH3 domains collect in cytoplasmic aggregates and inhibit the ability of 
these cells to form invadopodia.  Interestingly, while these mutations affect invadopodia 
formation, the ability to degrade extracellular matrix is maintained, albeit in a far less 
efficient and focalized manner than what is normally seen in this cell line.  The aggregates 
were identified as being phosphoinositide-rich endosomes due to the co-localization of 
endosomal markers like EEA1.  The loss of invadopodia formation was attributed to a 
retention of Src kinase in these perinuclear endosomes.  Current experimentation is focused 
on elucidating the mechanisms behind the observed results with particular focus on the 
putative intra and intermolecular Tks5 interactions that would drive the invasive/metastatic 
behavior of cancer cells. 
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Introduction 
 
Prologue 
            It is not uncommon for cells to control their most important cellular processes 
via the formation and function of macromolecular assemblies—transcriptional and 
translational regulatory complexes come to mind as examples.  
Podosomes/invadopodia are the macromolecular assemblies that govern the cellular 
process of motility and invasion.  Cancer cells, in particular, invoke the formation of 
invadopodia to drive the deadliest aspect of cancer progression called metastasis.  The 
purpose of this thesis project was to investigate the mechanism by which one of the 
most integral signal transduction pathways that govern invadopodia development 
functions.  This pathway is controlled by Src tyrosine kinase and its substrate, the 
adaptor and scaffolding protein Tks5.  A notorious feature of Tks5, but a feature of 
strikingly poor understanding, are its five SH3 domains, including the role they play 
in the assembly and function of invadopodial complexes in cancer cells.  In this thesis 
project, the SH3 domains were individually mutated, and then analyzed for their 
impact on invadopodia development.  This introduction seeks to better clarify the 
context of this objective by identifying the nature of metastasis, the signal 
transduction processes that regulate invadopodia development with emphasis on the 
roles of Src and Tks5, and the possible functions of Tks5 SH3 domains, including 
their potential as a therapeutic target for aggressive forms of cancer.     
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Src Signaling and Invadopodia Formation 
Src Signaling Mechanism 
The main cause of cancer patient morbidity and mortality is the spread of cancerous 
cells to distant sites in the body, a process known as metastasis.  To metastasize, cancer cells 
must invade the surrounding tissue through increased motility and degradation of the 
extracellular matrix (ECM) (Chang and Werb, 2001; Friedl and Wolf, 2003).  It is important 
to understand the invasive mechanisms responsible for metastasis in order to greatly improve 
cancer patient prognosis.  In the 1980’s, one such mechanism for metastasis was discovered.  
Fibroblasts transformed with Rous sarcoma virus (RSV) were shown to create actin-based 
protrusions with focalized protease activity towards the ECM (Chen et al., 1985; Chen, 1989; 
David-Pfeuty and Singer, 1980; Tarone et al., 1985).  Later, the viral protein pp60src was 
identified as being responsible for these morphological and functional changes (Chen et al., 
1985).  This transforming protein had in fact been derived from a cellular homolog, referred 
to as Src, which functions as a tyrosine kinase (Spector et al., 1978; Takeya and Hanafusa, 
1983).   
The Src family kinases are prominent nonreceptor tyrosine kinases involved in 
signaling transduction pathways that control multiple cellular processes such as cell-cycle 
regulation, survival, and cytoskeletal remodeling.  There are nine Src family kinases: Src, 
Fyn, and Yes, which are expressed in most tissues, and Blk, Yrk, Fgr, Hck, Lck, and Lyn, 
which exhibit more tissue-specific expression patterns.  Src is primarily involved in the 
development of human cancers due to its activation of pathways involved in cell 
proliferation, survival, and motility/invasion.  Activated Src can transform cells and induce 
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tumor formation, and Src expression and activity is often elevated in advanced stage 
carcinomas (Frame, 2002).    
Without the presence of a signal, Src is held in an inactive, closed conformation 
mediated by the binding of a phosphotyrosine residue at position 527 to its own Src 
homology 2 (SH2) domain (Figure 1).  Displacement of this intramolecular interaction can  
occur through higher affinity SH2 domain ligands, particularly the phosphotyrosines that are 
generated by activated receptor tyrosine kinases (Figure 1).  Following the unfolding of Src, 
the catalytic Y416, located in the activation loop, becomes autophosphorylated and Src is 
fully activated.  Due to this process, Src activity can be regulated by both phosphorylation 
Figure 1. Direct activation of Src by receptor tyrosine kinases.  An intramolecular 
interaction between the SH2 domain of Src and its phosphorylated Y527 residue holds 
it in an inactive, closed conformation.  Receptor tyrosine kinases are activated when 
bound to an extracellular signal, leading to autophosphorylation of their kinase 
domains.  The SH2 domain of Src preferentially binds these phosphorylated tyrosines 
on the receptor, disrupting the intramolecular binding of Src to create a catalytically 
active open conformation that enables Src autophosphorylation at Y416.  Src 
signaling functions in processes related to cytoskeletal reorganization (motility and 
invasion) and cell proliferation and survival.   
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and protein-protein interactions.  For example, Src signaling can be activated by the 
dephosphorylation of Y527 by tyrosine phosphatases, the deletion or mutation of Y527, or 
the phosphorylation of Y416 by other tyrosine kinases (Frame, 2002).  Interestingly, 
phosphorylation of Y416 is not sufficient to fully activate kinase activity.  Kinase activity is 
greatly increased when the Src Homology 3 (SH3) domain of Src has been displaced from an 
intramolecular interaction, possibly due to constraints this interaction may cause on the 
kinase domain (Moroco et al., 2014).   
Once released, the SH3 domain of Src binds to some of its substrates such as AFAP1 
and p130Cas, allowing for efficient substrate tyrosine phosphorylation and communication 
between the kinase and these two cytoskeletal regulatory proteins (Reynolds et al., 2014).  
The SH3 domain of Src is also important for its recruitment to cell-ECM bundling sites 
called focal adhesions via RhoA and Rho kinase.  Additionally, Src is activated at sites of 
cellular adhesion through SH3 domain interactions with integrin receptors (Playford and 
Schaller, 2004).  Through these mechanisms, Src is involved in activating pathways 
associated with cytoskeletal reorganization, which is necessary for increased motility and/or 
invasion.  
 
Invadopodia 
The invasive structures formed by Src activity are called invadopodia, for their 
likeness to invasive feet (Chen, 1989).  Invadopodia are dynamic, actin-rich cell surface 
protrusions with a diameter of 0.5 to 2 µm, and which extend 1 to 7 µm into the surrounding 
tissue (Chen, 1989; Schoumacher et al., 2010) (Figure 2).  These structures provide sites of 
adhesion to the ECM, but unlike focal adhesions have the added capability of being able to 
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degrade the surrounding tissue through proteolytic activity (Chen et al., 1984; Nakahara et 
al., 1997; Seals et al., 2005).  Following the discovery of invadopodia, four human melanoma 
cell lines were shown to both form invadopodia and invade through gelatin, fibronectin, and 
Matrigel, thus suggesting a hypothesis that invadopodia drive ECM degradation in vivo 
during cancer cell invasion and metastasis (Monsky et al., 1994).                                                                                
 
 
 
Src Signaling and Tks5 
As Src-transformed cells were shown to form invadopodia and Src was shown to 
localize to sites of matrix degradation, the Src signaling pathway has long been studied for its 
role in invadopodia development (Chen et al., 1985).  In 1998, a cDNA library was screened 
for novel Src substrates, revealing the tyrosine-phosphorylated protein FISH/Tks5 (Lock et 
al., 1998).  Tks5 is approximately 150 kDa in size (comprised of 1124 amino acids) and 
Figure 2.  Depiction of invadopodia formed by Src-transformed cells.  (A) Cartoon of a cancer 
cell forming invadopodia.  Proteolytic activity allows for degradation of the ECM and access to the 
surrounding tissue and vasculature.  (B) Src-transformed NIH3T3 fibroblast showing invadopodia 
formation through the co-localization (yellow) of the actin cytoskeleton (green) and the invadopodia 
marker protein Tks5 (red). Some invadopodia arrange into the rosette super structures shown in the 
image. Nuclei (blue).   
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contains one amino-terminal phox homology (PX) domain followed by five SH3 domains 
(Figure 3).  There are also two alternative splice sites that code for protein sequences lying 
on either side of the first SH3 domain of Tks5 leading to the expression of various Tks5 
splice forms of unknown functional consequence.  Tks5 contains three potential Src  
 
phosphorylation sites at Y552, Y557, and Y619, based on homology to consensus Src 
phosphorylation sites (Figure 3).  Tks5 tyrosine phosphorylation has been shown to be 
associated with cytoskeletal reorganization in Rat1 fibroblasts treated with platelet-derived 
growth factor (PDGF), the signaling molecule responsible for PDGF receptor tyrosine kinase 
as well as Src activation (Lock et al., 1998).   
Further study of the effect of Tks5 on the actin cytoskeleton of Src-transformed 
NIH3T3 fibroblasts revealed that Tks5 localizes to invadopodia (Abram et al., 2003).  Later, 
Tks5 was shown to be necessary for invadopodia formation and the associated ECM 
degradation carried out by Src-transformed fibroblasts, Bt549 breast cancer cells, and RPMI-
7951 melanoma cells (Seals et al., 2005).   
Src, as a tyrosine kinase, phosphorylates many invadopodia-associated substrates.  
Indeed. Src-dependent Tks5 phosphorylation at Y557 and Y619 has been shown to be 
important for invadopodia-associated matrix degradation, suggesting activation of Tks5 
Figure 3. Modular structure of Tks5. Tks5 has a lipid-binding phox homology (PX) 
domain, five Src homology 3 (SH3) domains, and numerous poly-proline motifs.  The 
tyrosine (Y) residues represent candidate Src phosphorylation sites at positions Y552, 
Y557, and Y619.  Tks5 also contains two alternative splice sites that code for protein 
sequences on either side of its first SH3 domain (orange).  
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through Src signaling (Burger et al., 2014; Stylli et al., 2009).  Additionally, tyrosine 
phosphorylation of Tks5 renders it accessible to binding by phosphotyrosine binding 
domains on other proteins.  One example of these interactions involves Nck adaptor proteins.  
Immunoprecipitation techniques were used to show that the SH2 domain of Nck mediated an 
association with Tks5 in a Src-inducible manner.  A Y557F mutation in Tks5 prevented 
tyrosine phosphorylation and abolished the interaction with Nck and invadopodia (Stylli et 
al., 2009).  Together, these data point to an important Src-Tks5 signaling circuit in the 
regulation of invadopodia development in cancer cells. 
 
Tks5 Function and Invadopodia Assembly 
Stages of Invadopodia Assembly   
Invadopodia formation occurs in stages, beginning with the initiation of signal 
transduction pathways responsible for assembling and activating invadopodia components.  
Shortly after these pathways are activated, cells develop invadopodia precursor structures 
that contain invadopodia-associated complexes, but which do not degrade ECM.  These 
protein complexes are responsible for stabilization of invadopodia and initiation of actin 
polymerization.  Invadopodia maturation occurs through sustained actin polymerization 
leading to protrusion of the cell membrane and focalized matrix degradation.  Finally, 
invadopodia are disassembled, thus allowing for continued invadopodia reassembly at the 
leading edge of cells.  The dynamic nature of invadopodia and their regulated turnover allow 
for efficient invadopodia function in the context of motility and invasion (Beaty et al., 2014).  
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Extracellular Stimuli Responsible for Invadopodia Development 
Extracellular stimuli activate invadopodia-formation pathways.  Stimuli involved in 
invadopodia formation include growth factors, phorbol esters (e.g. PMA), reactive oxygen 
species, or activation of Notch signaling in hypoxic environments (Figure 4) (Diaz et al., 
2013; Hoshino et al., 2013).   
  Transforming growth factor beta (TGF-β) binds to receptor serine/threonine kinases, 
which can either phosphorylate Ras/Raf kinase signaling pathway intermediates or can 
phosphorylate transcription factors known as Smads (Figure 4) (Lee et al., 2007).  Once 
phosphorylated, the Smads can partner with co-regulators to promote or repress transcription 
of specific genes (Varon et al., 2006).  In the case of cancer cell invasion, Smads have been 
shown to couple with the transcription factor Twist1 in order to upregulate PDGF receptor 
(PDGFR) expression.  This leads to an increase in invadopodia formation and invasion 
through stimulation with PDGF (Eckert et al., 2011).  Smads have also been shown to 
increase expression of Hic-5, a protein that is linked with the activation of the small GTP-
binding proteins RhoC and Rac1, along with Src (Pignatelli et al., 2012).  TGF-β treatment of 
aortic endothelial cells has also been linked to an increase in expression of the Rho GTPase 
Cdc42, leading to actin polymerization, and of the matrix metalloproteinases MT1-MMP and 
MMP9, leading to ECM degradation, both of which are important characteristics of 
invadopodia (Varon et al., 2006). 
 Both PDGF and the epidermal growth factor EGF bind to their respective receptor 
tyrosine kinases to activate the Ras/Raf kinase pathway, Src, and/or the Abl kinases Abl/Arg 
through direct phosphorylation (Figure 4).  The downstream substrates of these kinases are 
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then involved in invadopodia formation and activity (see below) (Murphy and Courtneidge, 
2011).   
Invadopodia formation can also be activated by stimuli other than growth factors.  For 
example, application of the phorbol ester PMA (phorbol-12-myristate-13-acetate) activates 
protein kinase C (PKC) to induce invadopodia formation through its kinase activity (Figure 
Figure 4. Extracellular stimuli leading to invadopodia formation. 
Signaling pathways are activated by extracellular stimuli in order to initiate 
invadopodia formation.  The stimuli depicted here include transforming 
growth factor β (TGF-β), stromal cell-derived factor 1 (SDF-1), ECM proteins, 
reactive oxygen species (ROS), other generalized growth factors (e.g. PDGF, 
EGF), phorbol esters (e.g. PMA), Notch, and G-protein coupled receptor 
(GPCR) activation by kisspeptins like KP-10.  
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4) (Crimaldi et al., 2009).  Chemokines have also been shown to signal invadopodia 
formation.  The chemokine receptor CXCR4 is activated by stromal cell-derived factor 1 
(SDF-1) and functions to activate Abl/Arg (Smith-Pearson et al., 2010).  
The presence of reactive oxygen species (ROS), such as the superoxide produced by 
NADPH oxidases, was recently shown to promote invadopodia formation in Src-transformed 
fibroblasts, SCC61 squamous carcinoma cells from a head and neck cancer, C8161.9 
melanoma cells, Bt549 breast cancer cells, and RPMI-7951 melanoma cells (Figure 4).  It is 
thought that ROS are able to activate invadopodia formation through oxidation of the 
regulatory regions of PKC and Src, resulting in open and catalytically active enzymes.  ROS 
can also transiently inhibit the catalytic activity of some tyrosine phosphatases, a family of 
enzymes that remove phosphate groups from tyrosine residues.  Src-transformed fibroblasts 
treated with ROS inhibitors showed a reduction in Tks5 phosphorylation.  For this reason, 
ROS may act locally to promote invadopodia formation by inhibiting phosphatase activity in 
a positive feedback loop and keeping Src and its substrates phosphorylated and activated for 
longer periods of time (Diaz et al., 2009). 
 Activation of the Notch signaling pathway in hypoxic environments has also been 
shown to induce invadopodia formation (Figure 4).  The Notch signaling pathway allows for 
cell-cell signaling through receptor interactions on neighboring cells.  For example, hypoxic 
environments can activate Notch signaling through an increase in its ligand Jagged-2.  When 
an interaction occurs, two cleavages occur in the Notch receptor, one of which releases an 
intracellular functioning transcriptional regulator called Notch intracellular fragment (NIC).  
NIC partners with hypoxia-inducible factor 1 alpha (HIF1α) to upregulate the expression of 
genes associated with the hypoxia response.  One of the upregulated genes, ADAM12, is a 
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transmembrane protease, which functions to activate latent growth factors and induce 
invadopodia formation through EGFR signaling (Diaz et al., 2013).   
 Matrix proteins can also stimulate invadopodia formation through activation of ECM 
receptors known as integrins (Figure 4).  When bound to ECM proteins, integrins signal to 
Src-FAK (focal adhesion kinase) complexes at focal adhesions.  Invadopodia are rich in 
integrins, therefore integrins are thought to play a similar role in activation of invadopodia 
formation through Src signaling (Playford and Schaller, 2004).   
 Finally, G-protein coupled receptor signaling has recently been associated with 
invadopodia formation.  Kisspeptins are peptide products that activate the G-protein coupled 
receptor KISS1R (Figure 4).  KISS1R can then directly bind to the EGFR to activate its 
signaling pathway.  Alternatively, KISS1R can bind to the adaptor protein β-arrestin2, which 
in turn activates EGFR and Erk1/2 resulting in formation of invadopodia (Goertzen et al., 
2015; Zajac et al., 2011).  
 
Invadopodia-Associated Intracellular Signaling Pathway Components  
Extracellular stimuli generally activate a host of intracellular second messengers, 
which carry out functions leading to cellular responses.  The pathways turned on through the 
aforementioned signaling events are regulated by the Ras pathway, Src kinases, and Arg/Abl 
kinases (Figure 5).  Receptor tyrosine kinases (e.g., PDGFR, EGFR) can phosphorylate and 
activate the adaptor protein Shc, which relays the signal through the adaptor protein Grb2 to 
Sos (Lee et al., 2007).  Sos, a Ras guanine nucleotide exchange factor, is then able stimulate 
the exchange of the GDP bound to Ras for a GTP molecule.  When bound to GTP, Ras is 
activated.  Thus, Ras binds to and activates Raf, Raf phosphorylates MEK, and MEK 
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phosphorylates Erk.  Erk is then implicated in activation of MMP expression (see below) 
(Moon et al., 2004).  Ras is also able to bind to and activate Ral effectors, resulting in 
implementation of exocyst-mediated vesicle trafficking, and Cdc42, both of which are 
involved in invadopodia maturation (Neel et al., 2012).  
Src tyrosine kinase has been extensively studied for its role in cancer cell invasion.  It 
plays an integral role in the regulation of each stage of invadopodia development, including 
disassembly (Boateng and Huttenlocher, 2012).  Cell surface Src is internalized at the plasma 
membrane and, upon growth factor stimulation, is recruited to sites of receptor tyrosine 
kinases through endosomal trafficking.  Once at these sites, Src interacts with and becomes 
Figure 5. Intracellular signaling leading to invadopodia formation.  
Intracellular second messengers involved in activating invadopodia formation and 
activity through kinase function.  
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activated by receptor tyrosine kinases.  Disruption of endosomal recycling machinery results 
in retention of inactive Src in the perinuclear region (Sandilands and Frame, 2008).  Protein 
kinase C (PKC) activity can also activate Src through direct phosphorylation of S12 and S48 
or by relaying phosphorylation signals through the adaptor protein AFAP-110.  Briefly, PKC 
phosphorylates AFAP-110, inducing a conformational change that renders AFAP-110 open 
and able to bind the SH3 domain of Src (Figure 6).  When AFAP-110 is bound to Src’s SH3 
domain, the structure of Src becomes open and active (Gatesman et al., 2004).  Additionally, 
Src can be activated by phosphatases such as PTP1B, which cleaves the inhibitory phosphate 
from Y527 of Src.  When dephosphorylated at this site, Src becomes active, phosphorylating 
numerous substrates involved in invadopodia formation, such as cortactin, dynamin, N-
WASp, Tks4, and Tks5 (Cortesio et al., 2008).  Cellular transformation by activated Src is 
sufficient to instigate invadopodia formation (Tarone et al., 1985).   
Src activity also leads to phosphoinositide-3 kinase (PI3K) activation (Figure 6).  
Upon activation, Src’s SH3 domain becomes available for interaction with the p85 subunit of 
PI3K.  Src is then able to phosphorylate PI3K on Y688 in order to render it available for 
activation by small GTPases (Figure 6) (Sun et al., 2003). Cells can also be stimulated with 
PMA in order to activate PKC and PI3K.   Active PI3K hydrolyzes ATP in order to 
phosphorylate phosphatidylinositols.  Among the products of PI3K activity is PI(3,4)P2, 
whose enrichment at the cell membrane in areas with active Src and PI3K allows for 
recruitment of invadopodia early precursor proteins with phospholipid binding domains.  
This step in the process is likely an initial trigger for invadopodia formation (Oikawa et al., 
2008).  
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Tks5 Localization 
The amino terminal PX domain of Tks5 has been shown to bind tightly to PI(3)P and 
PI(3,4)P2 in order to enable plasma membrane localization (Figure 6) (Abram et al., 2003).  
Mutations of R42 and R93 in the PX domain of Tks5 have been shown to disrupt its lipid 
binding capabilities (Abram et al., 2003).  Additionally, interference with the binding of 
endogenous Tks5 to lipids through overexpression of an isolated PX domain suppresses 
Figure 6. PI3K activation and Tks5 localization.  Src activation by receptor tyrosine kinases 
allows for an open conformation, rendering its SH3 domain available for binding to the p85 
subunit of PI3K.  Src then phosphorylates Y688 of PI3K, relieving it of its inhibitory function 
and allowing for activation by small GTPases.  Once active, PI3K transfers a phosphate group 
from ATP to the 3’ position of a phosphatidylinositol, creating PI(3)P, PI(3,4)P2, and 
PI(3,4,5)P3.  This enrichment of phosphatidylinositol phosphates at the membrane allows for 
localization of proteins with lipid binding domains.  For example, AFAP110 can be recruited to 
close proximity of inactive Src through its PH domain.  AFAP110 can then transmit activation 
signals from PKC (activated by PMA) to Src.  Additionally, while Tks5 gets activated by direct 
Src phosphorylation, PI3K supports the relocalization of Tks5 to the membrane surface via its 
lipid-binding PX domain where invadopodia formation occurs.  
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invadopodia formation in Src-transformed fibroblasts (Abram et al., 2003; Oikawa et al., 
2008).   
In order to better understand the significance of the lipid binding properties of Tks5, 
further studies focused on the localization of its isolated PX domain.  In normal fibroblasts, 
the isolated PX domain has a punctate distribution, similar to that seen by an isolated FYVE 
domain of Hrs, which is known to bind to PI(3)P in early endosomes.  In contrast, full length 
Tks5 shows a more uniform cytoplasmic distribution, suggesting the existence of a 
mechanism for regulating the lipid-binding properties of Tks5 (Abram et al., 2003).   
 Expression of a form of Tks5 lacking the PX domain (Tks5ΔPX) in RAW264.7 
macrophages results in large dot-shaped actin aggregates, possibly due to the inability of 
Tks5ΔPX to properly bind to PI(3,4)P2 at the plasma membrane (Oikawa et al., 2012).  This 
may also lead to cytoplasmic mis-localization of actin-associated Tks5 binding partners.  
This is different from full length Tks5, which is tightly regulated spatiotemporally.  Thus, it 
is likely that Tks5 exists in a conformation allowing for the masking of its PX domain prior 
to Src phosphorylation in order to activate the lipid-binding properties of Tks5 only upon 
localization to sites of activated Src (Oikawa et al., 2012).  In keeping with this hypothesis, 
Tks5 phosphorylation defective mutants, acting independently of Src, have been shown to 
localize to invadopodia-related structures called podosomes in osteoclasts, if there is 
displacement of Tks5’s closed conformation via the binding of its PX domain to PI(3)P and 
PI(3,4)P2 (Oikawa et al., 2012).   
Another study was done using MTLn3 rat mammary adenocarcinoma cells to assess 
invadopodia precursor development (Sharma et al., 2013).  The authors found that there is 
weak binding of Tks5 to the membrane due to basal levels of PI(3,4)P2 in invadopodia 
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precursors.  Recruitment of SHIP2, a 5’-inositol phosphatase, to invadopodia allows for 
further generation of PI(3,4)P2 through dephosphorylation of PI(3,4,5)P3 (Figure 5).  This 
added enrichment of PI(3,4)P2 allows for Tks5 binding stabilization leading to invadopodia 
maturation and ECM degradation.  Invadopodia are highly dynamic structures, and the 
reversible nature of Tks5/PI(3,4)P2 binding may contribute to this.  Reversing this binding 
destabilizes the precursor and allows for environmental influence on invadopodia through 
fluctuations in Src and PI3K activation.   
 
Formation of Early Precursor Invadopodia 
Another early invadopodia precursor protein, the small GTPase Cdc42, is also 
activated through phosphorylation by Src.  Cdc42 then binds to and activates the actin-related 
protein N-WASp by displacing an inhibitory intramolecular interaction (Figure 7) (Rohatgi et 
al., 2000).  Once active, N-WASp binds cortactin, which acts as a scaffold to bring the actin-
severing protein cofilin, N-WASp, and actin together at the plasma membrane.  N-WASp 
also binds to the actin-nucleating Arp2/3 complex in order to stimulate actin polymerization.   
N-WASp has also been shown to interact with Tks5 (Oikawa et al., 2008).  Similar to 
the lipid-binding PX domain of Tks5, N-WASp contains a WASp homology 1 (WH1) 
domain which is not only able to bind actin but can also interact with PI(4,5)P2.  It has been 
suggested that the interactions between N-WASp and PI(4,5)P2 help promote N-WASp 
activation at the plasma membrane (Rohatgi et al., 2000).  As lipid-binding Src substrates, 
both Tks5 and N-WASp have the potential to recruit one another to sites of invadopodia 
formation.  A study investigating invadopodia maturation in adenocarcinoma cells observed 
N-WASp localization to invadopodia prior to Tks5 localization (Sharma et al., 2013).  
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However, an earlier study carried out in Src-transformed fibroblasts suggested that Tks5 is 
instrumental in recruiting large quantities of N-WASp to sites of invadopodia formation 
(Oikawa et al., 2008).  Therefore, there is contradictory evidence as to whether N-WASp 
recruits Tks5 or vice versa. 
Src can also activate another tyrosine kinase called Arg.  Arg phosphorylates 
cortactin at Y421 (Figure 7).  The adaptor protein Nck is then recruited to sites of cortactin 
phosphorylation and has the ability to bind to cortactin, N-WASp, and Tks5 (Beaty et al., 
2013; Stylli et al., 2009).  Nck is able to induce N-WASp and Arp2/3-mediated actin 
polymerization, although the mechanism behind this is not well understood (Bravo-Cordero 
et al., 2011).  
Talin, a focal adhesion adaptor protein, has been shown to localize to early precursors 
by binding to actin and assists with the process of invadopodia maturation (Figure 7).  Once 
at precursors, talin binds to β1 integrins, then to moesin, a membrane-organizing protein.  
Moesin arrives to early invadopodia precursors bound to sodium-hydrogen exchanger 1 
(NHE1), which functions to increase the intracellular pH.  This change in the intracellular 
environment leads to cofilin release from cortactin, thus allowing for cofilin activation on site 
(Beaty et al., 2013). Upon its release, cofilin is able to carry out its actin-severing abilities, 
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generating free actin barbed ends and allowing for branched actin polymerization by Arp2/3 
(Figure 7) (Bravo-Cordero et al., 2011).   
 
Tks5 Adaptor and Scaffolding Functions 
Following the formation of the early precursor invadopodia and initial actin 
polymerization, a large number of proteins are recruited to the site in which mature 
invadopodia will develop.  The proteins found at these sites exist at the centers, or cores, of 
invadopodia.  The early precursor proteins Tks5, Nck, and cortactin function as adaptor 
proteins to bring complexes together at these sites. 
Figure 7. Formation of invadopodia early precursors.  Proteins involved in the formation 
of early invadopodia precursors are responsible for initiating polymerization of actin (red) at 
the site. The numbering and black arrow show the progression of protein recruitment to the 
site as described in the text.  
	 19	
Tks5 clusters the structural and enzymatic components of invadopodia, most likely 
through its SH3 domain-associated, protein-binding properties (Eckert et al., 2011).  The five 
SH3 domains of Tks5 are known to mediate interactions with poly-proline motifs on other 
proteins (Figure 8A).  In addition, Tks5 has three poly-proline motifs located between these 
domains, which can bind to SH3 domains on other proteins (or to one of its own SH3 
domains) (Figure 3) (Crimaldi et al., 2009).  Tks5 also has a poly-proline motif located 
within its PX domain (Figure 3) (Lock et al., 1998).  
 GST-SH3 domain pull down assays suggest that the 3rd and 5th SH3 domains of Tks5 
have the largest number of binding partners (Abram et al., 2003).  These GST pull down 
experiments along with co-immunoprecipitation assays have helped identify some of these 
binding partners.  In Src-transformed fibroblasts, the microtubule-associated protein 
dynamin2 can bind the 1st and 5th SH3 domains (Figure 8A), tubulin can bind the 3rd SH3 
domain, and zyxin, an actin-associated zinc binding protein, can bind the 3rd and 5th SH3 
domains of Tks5 (Oikawa et al., 2008).  Nogo-B, an endoplasmic reticulum protein recently 
associated with the cytoskeleton, can also bind the 5th SH3 domain of Tks5 (Oikawa et al., 
2008; Schanda et al., 2011).  And finally there is evidence that F-actin itself can bind the 5th 
SH3 domain of Tks5 as well (Oikawa et al., 2008).  N-WASp is capable of binding to all five 
SH3 domains of Tks5.  In this case, full length Tks5 is able to more efficiently bind N-WASp 
than the isolated SH3 domains.  The binding between Tks5 and N-WASp may also be 
constitutive, occurring with or without activation by Src (Oikawa et al., 2008), though this 
does not explain the ability of these proteins to recruit the other during invadopodia 
formation.  WASp-interacting protein (WIP), a protein involved in stabilizing N-WASp, can 
bind the 3rd and 5th SH3 domains of Tks5 (Figure 8A) (Oikawa et al., 2008).   
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Figure 8. Binding Partners of Tks5. (A) Diagram of Tks5 with binding partners according 
to binding site.  (B) Chart of Tks5 binding partners without an identified site of binding.  
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 Using a phage display screen in Src-transformed fibroblasts, ADAMs family matrix 
metalloproteases, specifically ADAMs 12, 15, and 19, were shown to bind to the 5th SH3 
domain of Tks5 via poly-proline motifs in their cytoplasmic tails (Figure 8A).  This 
interaction was confirmed by a co-immunoprecipitation assay (Abram et al., 2003).  The 
ADAMs (a disintegrin and metalloprotease) family proteases act as membrane-bound 
sheddases to modify cell-cell interactions and to release active signaling molecules such as 
growth factors and cytokines from the cell surface or the ECM (Seals and Courtneidge, 
2003).  It has been suggested that the association between Tks5 and ADAMs may contribute 
to the regulation of ADAMs enzymatic activity (Abram et al., 2003; Rufer et al., 2009).   
 The tandem 1st and 2nd SH3 domains of the short form of Tks5 (lacking both of the 
alternatively spliced exons; see Figure 3) have a very high similarity to the two SH3 domains 
of p47-phox, a component of the NADPH oxidase.  The SH3 domains of p47-phox are 
known to function as a superSH3 domain, a continuous binding surface with a very high 
affinity for a single ligand.  There is evidence in Src-transformed fibroblasts that the first two 
SH3 domains of Tks5 similarly function as a superSH3 domain to bind Sos1, an activator of 
Ras and Rac GTPase activity, as well as to dynamins 1 and 2 (Figure 8A) (Rufer et al., 
2009).   
 Additionally, the 5th SH3 domain of Tks5 is known to recruit AFAP-110, cortactin, 
and p190RhoGAP to podosomes formed by A7r5 rat smooth muscle cells (Figure 8A).  
Cortactin promotes actin polymerization, while p190RhoGAP downregulates RhoA activity 
and inhibits stress fiber and focal adhesion formation, thus enabling new invadopodia 
development.  However, Tks5 failed to co-immunoprecipitate with any of these three 
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proteins suggesting a possible indirect interaction mediated through additional proteins 
(Crimaldi et al., 2009).   
 A comprehensive study of SH3 domains using HEK293 human embryonic kidney 
cells found an interaction between the transiently expressed GST-SH3A of Tks5 and ITCH.  
ITCH is an E3 ubiquitin ligase that has been shown to be involved in an epithelial to 
mesenchymal transition (EMT), a developmental program associated with an invasive 
phenotype that is often reactivated in cancer cells (Figure 8A).  This interaction remains to be 
fully investigated (Carducci et al., 2012; Salah et al., 2014).   
 Perhaps the most comprehensive study of Tks5 binding partners involved a co-
immunoprecipitation assay in HEK293T cells transiently expressing a full-length Tks5 
construct.  This experiment was able to identify a large number of potential binding partners, 
most of which have not been investigated any further (Figure 8B) (Supplemental Table SI) 
(Stylli et al., 2009).  Interestingly, another study involving co-immunoprecipitation in 
osteoclasts found that Tks5ΔPX was able to bind to more proteins than full length Tks5.  
This suggests that the PX domain somehow interferes with the binding capabilities of Tks5, 
possibly by sequestering Tks5 in a closed and inactive conformation as discussed previously 
(Oikawa et al., 2012).   
A study using Src-transformed fibroblasts demonstrated that the adaptor protein Grb2 
precedes Tks5 at areas of invadopodia formation (Figure 9A) (Oikawa et al., 2008).  The N-
terminal SH3 domain of Grb2 has been shown to bind to a poly-proline motif of Tks5, and 
this complex is formed at invadopodial structures.  For this reason, Grb2 may assist in 
targeting Tks5 to invadopodia.  Tks5 is also known to recruit Nck adaptor proteins to 
invadopodia.  N-WASp and dynamin2 follow shortly after, thus allowing for actin 
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polymerization and invadopodia maturation (Oikawa et al., 2008).  In a separate study 
involving MTLn3 rat mammary adenocarcinoma cells, cortactin, N-WASp, the actin-
severing protein cofilin, and F-actin were shown to localize before Tks5 recruitment to 
invadopodia (Figure 9B).  In this case, the cortactin-actin complex is thought to function in 
the recruitment of N-WASp and cofilin.  N-WASp may then assist in the subsequent 
localization of Tks5.  Binding of Tks5 to PI(3,4)P2 at the plasma membrane 
would then stabilize these invadopodia precursors (Sharma et al., 2013).  Thus, it is possible 
that the nature of Tks5 binding may differ based on cell type and mode of activation. 
Taken together, invadopodia formation is triggered by extracellular signaling 
allowing for activation of several second messengers.  Included among these is Src tyrosine 
Figure 9. Roles for Tks5 in early invadopodia precursor formation. (A) In Src-
transformed fibroblasts, Grb2 precedes Tks5 at invadopodia and may assist in targeting 
Tks5 to the membrane.  Tks5, in turn, recruits N-WASp and dynamin2 to the early 
precursor for subsequent actin polymerization (Oikawa et al., 2008).  (B) In MTLN3 
cells, cortactin and F-actin localize first and recruit N-WASp and cofilin for actin 
polymerization.  Tks5 localizes next to stabilize the structure through interactions with 
the plasma membrane (Sharma et al., 2013).   
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kinase at the plasma membrane.  Here, Src phosphorylates Tks5 on Y557 and Y619 in order 
to promote accessibility of its PX domain.  The PX domain of Tks5 is then free to bind 
PI(3,4)P2 generated at the plasma membrane by PI3K and SHIP2.  Then, Tks5 is able to bind 
other proteins through its SH3 domains, phosphotyrosines, and poly-proline motifs.  The 
ability to bind other proteins gives Tks5 its scaffolding function, allowing it to bring protein 
complexes together at sites of activated Src in order to potentiate invadopodia development.   
 
Tks4 
There is a protein known as Tks4, which is similar in domain structure to Tks5, but 
with a lipid-binding PX domain followed by four SH3 domains (Buschman et al., 2009).  
Tks4 is also found to localize at invadopodia through interactions with PI(3,4)P2 and has 
been shown to be necessary for complete formation of these structures.  Knockdown of Tks4 
results in accumulation of Tks5 and other invadopodia-related proteins at the plasma 
membrane, but actin polymerization does not take place.  However, this loss of invadopodia 
due to Tks4 depletion can be rescued by Tks5 overexpression, thus suggesting that these 
related proteins may have some overlapping roles in recruiting proteins to sites of 
invadopodia formation for actin polymerization (Buschman et al., 2009).   
 
Formation of Late Precursor Invadopodia 
N-WASp, Arp2/3, and cofilin function to polymerize actin at the site of invadopodia, 
allowing for protrusion of the cell membrane (Figure 10).  Another actin adaptor protein, α-
actinin, bundles actin microfilaments together and links actin to integrin receptors (Sjoblon et 
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al., 2008).  α-actinin is found at invadopodia bound to the Tks5 and WIP binding partner 
Zyxin (Oikawa et al., 2008; Sjoblon et al., 2008).  
β1 integrin binding to ECM ligands stabilizes developing invadopodia structures and 
triggers their maturation (Figure 10).  Focal adhesion adaptor proteins such as Hic-5, paxillin, 
vinculin, and the aforementioned integrin receptors are found in an adhesion ring 
surrounding the invadopodia core where they further stabilize the structure for invadopodia 
Figure 10. Formation of late precursor invadopodia. Scaffolding 
proteins are responsible for recruiting more actin-associated proteins, and a 
vesicle targeting system is established for further recruitment of 
components.  
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maturation (Figure 10) (Pignatelli et al., 2012).  The integrins in the surrounding adhesion 
rings have been shown to bind to paxillin, which in turn binds to integrin-linked kinase 
(ILK).  ILK is then able to recruit its binding partner IQGAP1, a polarizing protein involved 
in vesicle trafficking.  This is though to prepare the precursor site for focalized delivery of 
invadopodia components for efficient matrix degradation (Branch et al., 2012). 
 
Invadopodia Maturation and Disassembly 
Invadopodia Maturation Through Elongation 
In order to elongate invadopodia protrusions during maturation, it is necessary for the 
cell to generate both branched and unbranched actin microfilaments.  The branched actin is 
maintained at the base of invadopodia by the proteins responsible for the initiation of actin 
polymerization, such as N-WASp, cortactin, cofilin, and Arp2/3 (Figure 11).  The 
unbranched actin is created by the formin mDia2, which prevents capping of actin 
microfilaments while simultaneously nucleating new actin polymerization.  VASP proteins 
such as MenaINV are also responsible for protection from capping and they function to bundle 
actin filaments at the growing ends.  Cross-linker fascins are also present, being responsible 
for the bundling of unbranched actin filaments and promoting their stability within maturing 
invadopodia (Figure 11) (Schoumacher et al., 2010).   
Cofilin remains active within mature invadopodia as it is responsible for regenerating 
barbed ends for continued actin polymerization.  RhoGTPases are also present in 
invadopodia.  Indeed, the entire Rho family, though particularly RhoC, is able to activate the 
Rho kinase ROCK.  Once active, ROCK phosphorylates and activates LIM kinase (LIMK), 
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which in turn phosphorylates cofilin on S3 to prevent its actin-severing activity.  14-3-3ε can 
bind this phosphorylated S3 on cofilin to prevent its dephosphorylation and lock it in an 
inactive state (Figure 11) (Bravo-Cordero et al., 2011).  Because RhoC activity leads to a loss 
in cofilin activity, p190RhoGAP, the protein responsible for RhoC inactivation, is recruited 
to invadopodia cores and activated by β1 integrin (Beaty et al., 2013; Bravo-Cordero et al., 
2011).  Alternatively, p190RhoGEF is present in the rings surrounding invadopodia where it 
can activate RhoC to its GTP bound state, leading to the phosphorylation-dependent loss of 
cofilin activity.  This allows for actin polymerization to be focalized at invadopodia, while 
promoting elongation at the site at the same time (Figure 11) (Bravo-Cordero et al., 2011).  
Figure 11. Elongation of mature invadopodia. Elongation of invadopodia involves 
branched and unbranched actin (red), intermediate filaments (green), and microtubules 
(blue). Actin polymerization surrounding invadopodia is regulated, allowing for 
focalized invadopodia development.  
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p190RhoGAP also leads to a decrease in RhoA activity at invadopodia cores, allowing for 
disassembly of stress fibers and focal adhesions.  This prevents any actin-associated 
machinery from being retained in actin-related structures other than invadopodia, i.e. focal 
adhesions (Crimaldi et al., 2009). 
Microtubules along with vimentin and keratin intermediate filaments are also present 
at invadopodia.  They stabilize these invadopodia structures and support the movement of 
cells through the degraded extracellular space (Figure 11).  Microtubules and vimentin 
intermediate filaments are only found in mature invadopodia and are required for the 
maturation process (Schoumacher et al., 2010).   
 
Matrix Degradation by Mature Invadopodia 
Invadopodia-associated ECM degradation is linked to proteolytic activity, specifically 
by the transmembrane proteases MT1-MMP, seprase, and ADAMs family proteases as well 
as by secreted MMPs like MMP2 and MMP9 (Figure 12).  These proteases digest  
ECM components like collagen, fibronectin, and laminins (Weaver, 2006).   
Protease expression is regulated by NF-κB and AP-1 transcription factor activation 
downstream of Erk1/2 signaling (Figures 5 and 12) (Moon et al., 2004).  Once proteases are 
synthesized, they are packaged for vesicle trafficking to sites of invadopodia formation (Hu 
et al., 2011).  Endophilin A2 generates membrane curvature for vesicle formation, and 
dynamin2 functions as a pinchase to dissociate vesicles from the trans-Golgi network (Figure 
12) (Krutchen and McNiven, 2006).  Rab proteins, particularly Rab8 and Rab40b, have been 
found to be associated with protease trafficking to invadopodia (Jacob et al., 2013; Poincloux 
et al., 2009).  Rabs are GTPases involved in the compartmentalization of vesicle contents, 
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Figure 12. Degradation by mature invadopodia. Microtubules (blue) allow for 
vesicular delivery of MMPs and other proteases to invadopodia to allow for 
degradation of the surrounding matrix. 
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and the tethering and targeting of vesicles to organelles.  Cytosolic inactive Rabs bound to a 
GDP molecule interact with REPs (Rab escort proteins), which help target Rabs to organelle 
membranes.  Once at their target membranes, inactive Rabs are subject to activation by 
RabGEFs.  Once bound to GTP, Rabs are incorporated into vesicles where they can interact 
with effectors such as motor proteins and tethering complexes to ensure that vesicles are 
delivered to the proper location in the cell (Figure 12) (Sandoval and Simmen, 2012).   
Motor proteins such as kinesins and myosins have been associated with trafficking of 
proteins to invadopodia, and it is thought that they use microtubules to deliver proteins to the 
invadopodia core.  IQGAP1 has been thought to play a role in anchoring microtubules at sites 
of invadopodia to allow for directed trafficking of components like MT1-MMP (Figure 12) 
(Poincloux et al., 2009).  Once at invadopodia, vesicles are brought closer to the membrane 
through the exocyst, a complex comprised of eight subunits that can interact with 
microtubules and motor proteins and, once in close proximity to the plasma membrane, 
PI(4,5)P2.  The exocyst allows for SNARE proteins (e.g., Ti-VAMP) located both in the 
vesicle and at target membranes to associate and drive membrane fusion (Figure 12) (Synek 
et al., 2014).  IQGAP1 has also been shown to bind to the exocyst through interactions with 
RhoA and Cdc42, thus allowing for targeted delivery of MT1-MMP at the plasma 
membrane.  Fusion of the vesicle with the plasma membrane allows for proper placement of 
transmembrane proteases or secretion of pro-MMPs at ECM contact sites (Poincloux et al., 
2009).   
 MT1-MMP is activated on its way from the Golgi apparatus by furin-like 
convertases, which cleave off the pro-peptide (Osenkowski et al., 2004).  Once embedded in 
the plasma membrane, MT1-MMP activates secreted MMP2 and MMP9 through cleavage of 
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their pro-peptide domains (Figure 12).  This activation is facilitated by MT1-MMP binding to 
integrins like αvβ3.  These MMPs then collectively function to digest the ECM, and release 
sequestered growth factors in the process (Clark et al., 2007).  MT1-MMP has also been 
shown to activate latent growth factors and cellular receptors such as those involved in Notch 
signaling through its sheddase activity (Osenkowski et al., 2004).   
Interestingly, depletion of the adaptor protein Tks4 results in a loss of accumulation 
of MT1-MMP at invadopodia and an inability to degrade ECM (Buschman et al., 2009).  It 
has been suggested that Tks4 holds a significant role in MT1-MMP localization, although the 
precise role it plays has not been elucidated.   Since Tks4 and Tks5 appear to have some 
overlapping roles in terms of actin polymerization, Tks5 was overexpressed in Tks4-depleted 
cells to identify any redundant roles in MT1-MMP localization.  However, ECM degradation 
was unable to be rescued, suggesting that this specific function is unique to Tks4 (Buschman 
et al., 2009).   
 The ADAMs family of metalloproteinases function as sheddases to modulate integrin 
function, mediate cell-matrix interactions, and activate latent transmembrane growth factors 
(Figure 12) (Stautz et al., 2010).  In addition, ADAMs family members have been shown to 
degrade matrix proteins like collagen and fibronectin (Roy et al., 2004).  Tks4 and Tks5 have 
both been shown to associate with ADAMs family proteases, however the functional 
implications behind these interactions have yet to be discovered (Courtneidge, 2012).   
β1 integrin recruits seprase, a membrane-bound gelatinase, to invadopodia cores 
(Beaty et al., 2013).  β3 integrins recruit MMP2 to the cell surface as well.  This suggests that 
integrins may play a general role in targeting proteolytic activity at invadopodia, possibly due 
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to the need for coordination between matrix-targeting proteolysis with sites of ECM contact 
(Mueller et al., 1999).   
 Tissue inhibitors of metalloproteinases (e.g., TIMP1 and TIMP3), as the name 
implies, inhibit MT1-MMP by directly binding to the enzyme’s active site (Figure 12).  
Interestingly, however, MT1-MMP bound to TIMP2 still maintains the ability to activate 
MMP2.  In addition, low concentrations of TIMP2 are essential for the efficient activation of 
MMP2, allowing for recruitment of MMP2 to active MT1-MMP molecules.  This suggests 
that TIMP2 functions to promote MMP2 activation (Lu et al., 2004; Murphy and 
Courtneidge, 2011).  Proteolytically inactive MT1-MMP is internalized through caveolar- or 
clathrin-mediated endocytosis (Poincloux et al., 2009).  The Cdc42-interacting protein CIP4 
assists in this process, instigating membrane invagination at these sites (Figure 12).  When 
CIP4 is phosphorylated by Src on Y471, its activity is inhibited, thus allowing for the 
accumulation of MT1-MMP at invadopodia (Hu et al., 2011).  β1 integrin interaction with 
MT1-MMP has also been shown to inhibit MT1-MMP endocytosis, further supporting the 
function of integrins in proteolytic activity.  However, once internalized, MT1-MMP is 
transported to the lysosome for degradation, though a fraction of internalized MT1-MMP is 
recycled through the trans-Golgi network for regeneration of active enzyme at the cell 
surface (Figure 12) (Poincloux et al., 2009).   
 While endocytosis is used as a means of clearing inactive enzyme from the cell 
surface, it is also used to clear cleaved ECM from the extracellular space.  Integrin-mediated 
ECM endocytosis has been proposed as a mechanism of internalizing cleaved matrix proteins 
for lysosomal degradation (Shi and Sottile, 2011).  This process allows for removal of ECM 
from the surrounding space in order to provide room for the cell to move through.  
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Invadopodia Disassembly  
Invadopodia turnover is equally important for efficient invasion because it refocuses 
ECM degradation to sites where it is needed.  Additionally, invasion pathways can be 
switched to motility pathways, allowing for movement through the newly degraded tissue 
(Poincloux et al., 2009).  Optimally concerted proteolytic activity and motility must be 
achieved for maximum invasive potential (Moshfegh et al., 2014).   
In order for invadopodia to disassemble, the activity of the main components of 
invadopodia must be inhibited.  The actin-binding protein caldesmon (CaD), a p53 
transcriptional target, downregulates invadopodia formation by competing with Arp2/3 
(Figure 13) (Mukhopadhyay et al., 2009; Yoshio et al., 2007).  Expression of CaD decreases 
invadopodia formation and increases the incidence of stress fibers by preventing actin 
polymerization (Yoshio et al., 2007).   
 As previously discussed, CIP4 is involved in instigating MT1-MMP endocytosis and 
has been associated with inhibition of degradation by invadopodia.  In this way, CIP4 activity 
could also play a role in invadopodia disassembly (Figure 13) (Hu et al., 2011).   
 Trio, a guanine exchange factor, has been shown to be involved in invadopodia 
disassembly by activating Rac1.  Rac1, in its active GTP-bound state, is able to bind to 
numerous downstream effectors to trigger responses.  One of the effectors activated by Rac1 
is Pak1, or p21-activated protein kinase 1.  Pak1 is a serine/threonine kinase, which 
phosphorylates cortactin on S113 to destabilize cortactin-actin interactions and inhibit actin 
polymerization (Figure 13) (Moshfegh et al., 2014).    
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The tyrosine phosphatase PTP-PEST localizes to invadopodia and induces 
invadopodia disassembly through dephosphorylation of Src substrates involved in 
invadopodia formation and activity.  Conversely, it has been suggested that the presence of  
 
PTP-PEST and other tyrosine phosphatases may allow for rapid turnover of protein 
complexes leading to more efficient invasion (Figure 13) (Diaz et al., 2009).   
Src phosphorylates paxillin Y31 and Y118, leading to activation of Rac1, possibly 
through the adaptor protein Crk.  The activation of Rac1 results in Erk activity.  Erk in turn 
activates calpains by phosphorylation on S50 (Badowski et al., 2008; Franco and 
Huttenlocher, 2005).  Calpains are intracellular Ca2+-dependent thiol proteases that have been 
Figure 13. Disassembly of invadopodia. The tightly regulated disassembly of 
invadopodia occurs through deactivation of the components allowing for rapid 
turnover and more effective degradation.   
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shown to regulate disassembly of podosomes.  Moderate calpain2 expression is associated 
with increased degradation and invasion, due to the importance of efficient invadopodia 
turnover.  It functions to cleave proteins such as paxillin, cortactin, N-WASp, and PTP1B 
(Figure 13).  Once cleaved, PTP1B is activated and is able to cleave the inhibitory phosphate 
of Src leading to its activation.  This may provide a pathway for subsequent invadopodia 
formation allowing for rapid turnover of protein complexes and efficient invasion (Cortesio 
et al., 2008).  
 
Regulation of Tks5 Gene and mRNA Expression 
SH3PXD2A 
 Since Tks5 is required for invadopodia formation and stability through recruitment of 
accessory proteins, it is prudent to consider how Tks5 is regulated in cells.  Human Tks5 is 
encoded by the gene SH3PXD2A (sometimes referred to as SH3MD1), a 267 kb gene 
containing 15 exons located on chromosome 10 (Figure 14).  The closest homolog to 
SH3PXD2A, with 47% homology, is SH3PXD2B, the gene encoding Tks4 (Cejudo-Martin et 
al., 2014).  Interestingly, simpler organisms such as the tunicate Ciona intestinalis and the 
sea urchin Strongylocentrotus purpuratus each contain one gene encoding for a Tks protein 
containing a PX domain followed by three or four SH3 domains, respectively.  This suggests 
that both SH3PXD2A and SH3PXD2B may have evolutionarily arisen from a single common 
gene (Buschman et al., 2009).  
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There are recognition sites for a wide variety of transcription factors in close 
proximity to the SH3PXD2A gene according to a SABiosciences’ DECODE database search, 
however not much is known about the factors regulating Tks5 expression at the gene level 
(Figure 15).  The DECODE database identified the ten most relevant transcription factors 
with potential regulation of SH3PXD2A gene expression through automated text-mining of 
published papers and use of the UCSC genome browser, a collection of annotated genomes.  
These transcription factors include AML1a, a transcription factor associated with 
proliferation of acute myeloid leukemic cells (Liu et al., 2009), c-Myc, a very common 
Figure 14. SH3PXD2A, Tks5 mRNA, and Tks5 protein domain structure.  The gene for Tks5, 
SH3PXD2A or SH3MD1, is located on chromosome 10 at 10q24.33 (Gene Cards human gene 
database).  SH3PXD2A contains 15 exons (blue), with a possible alternative transcriptional start 
site located at exon 6 (dashed red), resulting in a Tks5 isoform lacking the PX domain (Cejudo-
Martin et al., 2014; NCBI Gene; UCSC Genome Browser).  The mRNA of Tks5 contains two 
alternatively spliced exons (orange) conforming to exons 7 and 10 (Cejudo-Martin, 2014; NCBI 
Nucleotide).  Tks5 protein contains one amino terminal PX domain followed by five SH3 
domains.  Polyproline motifs (PXXP; light grey), and candidate Src phosphorylation sites (Y) are 
noted (NCBI Conserved Domain Database).    
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oncogene that promotes cell proliferation (Lin et al., 2012), and the glucocorticoid receptors, 
which have been shown in the past to initiate anti-apoptotic signaling in breast epithelial cells  
 
but operate in a cell-type specific manner (Skor et al., 2013).  Other transcription factors 
include AhR, a ligand-activated transcription factor that regulates differentiation of certain 
immune cells (Hughes et al., 2014), the SREBPs, which are sterol regulatory element-binding 
proteins involved in lipogenesis (Shao and Espenshade, 2012), and p53, the tumor suppressor 
that serves as a regulator of cell-cycle arrest and apoptosis (Wei et al., 2006).  
It has been noted in the literature that there is an NFATc1 recognition site located 
upstream of the SH3PXD2A gene (Oikawa et al., 2012).  NFATc1 is a transcription factor 
found in activated T cells, however it has been suggested that tumor cells may fuse with 
Figure 15. Transcription factors with binding sites in close proximity to the 
SH3PXD2A gene.  Ten most relevant transcription factors that bind from 20kb upstream to 
10kb downstream of the Tks5 transcriptional start site (red arrow; 105,605,164 to 
105,635,164 of chromosome 10).  Adapted from SABiosciences’ DECODE database.  
Transcription factors include acute myeloid leukemia protein 1 (AML1a), aryl hydrocarbon 
receptor (AhR), oncogenic c-Myc, the sterol regulatory element-binding proteins (SREBP), 
the tumor suppressor p53, and the glucocorticoid receptors (GR).  
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immune cells located in the tumor microenvironment to acquire the protein (Oikawa et al., 
2013).  Cell-cell fusion between immune cells and cancer cells has been shown to occur in 
vivo, so immunological regulation of Tks5 expression is possible (Oikawa et al., 2012).  
Acquired NFATc1 expression in tumor cells has also been linked to the induction of Snail 
and Zeb1, two transcription factors that activate EMT programming (Oikawa et al., 2013).  
Tks5 mRNA and protein levels have been elevated in RAW264.7 macrophages 
treated with receptor activator of NF-κB ligand (RANKL), a factor involved in bone 
metastasis (Oikawa et al., 2012).  Tks5 mRNA and protein levels were also elevated in A549 
human pulmonary carcinoma cells treated with transforming growth factor beta (TGF-β), 
another EMT activator.  NFATc1 is known to be activated downstream of RANKL 
stimulation, however the mechanism behind TGF-β-induced Tks5 expression is largely 
unknown.  Further understanding of the naturally available transcription factors responsible 
for Tks5 expression could elucidate these pathways.   
There is an alternative promoter found within the fifth intron of SH3PXD2A that 
promotes transcription at exon 6 and generates a Tks5 isoform lacking the PX domain 
(Figure 14).  This isoform is targeted for proteasomal degradation in Src-transformed 
fibroblasts, as it accumulates upon treatment with various proteasome inhibitors (Cejudo-
Martin et al., 2014).  Additionally, while a Tks5 mRNA ratio favoring the full length Tks5 is 
associated with metastatic lung adenocarcinoma, an mRNA ratio favoring the isoform 
lacking the PX domain is associated with nonmetastatic primary tumors (Li et al., 2013).  
This not only suggests isoform switching in the context of lung tumor progression, but also 
confirms that the functionality of Tks5 is highly regulated by its PX domain.  
	 39	
Upstream of SH3PXD2A there are at least three cytosine- and guanine-rich (CG-rich) 
islands (CGIs).  CGIs, when methylated, silence gene transcription.  These particular CGIs 
have been shown to be hypermethylated in the placentas of women with pregnancy-
associated high blood pressure, or preeclampsia.  It has been suggested that the 
downregulation of Tks5 expression through promoter methylation could in turn downregulate 
the invasion of trophoblast cells, thus allowing for preeclampsia development (Xiang et al., 
2013).  The invasion of trophoblast cells into the myometrium is necessary for successful 
pregnancy and requires similar invasion machinery to tumor cells.  Insufficient invasion 
leads to a reduction in blood flow to the fetus and fetal hypoxia, features seen in 
preeclampsia (Zhu et al., 2012).  Although this is the only known epigenetic regulation of 
SH3PXD2A that has been studied, it does bring up the possibility of epigenetic control of 
Tks5 expression in cancer cell invasion as well.   
 
Tks5 mRNA  
As previously mentioned, SH3PXD2A contains two alternative splice sites at exons 7 
and 10 (Figure 14).  These splice sites suggest at least four possible alternative splice forms 
(short, AS1, AS2, long), but it is speculated that a total of at least 12 different Tks5 mRNA 
transcripts could be expressed based on the presence of undiscovered alternative promoters in 
SH3PXD2A introns.  It is further possible that all of these Tks5 isoforms potentially could 
hold differential roles in tumor progression (Cejudo-Martin et al., 2014).   
Some cell lines, such as MCF7 breast cancer cells, have Tks5 mRNA transcripts but 
little, if any, protein, suggesting methods of regulating gene expression at the mRNA level 
(Seals et al., 2005).  One of these mechanisms may be through microRNA expression.  
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MicroRNAs have the ability to target and block translation of specific mRNAs.  Tks5 
mRNAs have been shown to be a target of miR-200c, an established EMT suppressor.  Upon 
transient overexpression of miR-200c in MDA-MB-231 breast cancer cells, there was a 
reduction in Tks5 mRNA and protein, and these normally invasive cells acquired an 
epithelial phenotype with diminished invasive capacity.  Interestingly, when miR-200s were 
inhibited in MCF7 cells, Tks5 mRNA levels increased, though Tks5 protein levels remained 
unchanged.  This indicates that Tks5 is not only subject to microRNA regulation, but that 
there are also currently unidentified mechanisms of Tks5 regulation at the mRNA and/or 
protein level in order to explain the lack of Tks5 in the MCF7 cell line (Sundararajan et al., 
2015).   
 
Targeting Tks5 SH3 Domains as a Cancer Metastasis Therapeutic 
SH3 Domains 
With further understanding of the roles that the individual SH3 domains of Tks5 play 
in invadopodia formation and cell invasion, specific interactions can be identified as potential 
targets for metastasis.  SH3 domains were first discovered when a region of Crk was 
characterized.  This region was identified as a Src homology 3 domain based on its homology 
to the third modular region of Src tyrosine kinase (Mayer et al., 1988).  Several years later, 
the isolated SH3 domain of Abl tyrosine kinase was used to identify the regions within two 
of its binding proteins, 3BP1 and 3BP2, which interact with the kinase.  Both binding motifs 
were identified as proline-rich regions, allowing for categorization of SH3 domains as 
proline-recognition domains (Ren et al., 1993).  The SH3 domain is just one member of a 
larger proline-recognition domain superfamily.  This superfamily is also comprised of the 
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WW (named for two conserved tryptophans), EVH1 (Ena/VASP homology domain 1), GYF 
(glycine-tyrosine-phenylalanine), profilin, and UEV (ubiquitin E2 variant) subfamilies 
(Carducci et al., 2012).  It is unlikely that proline-recognition domains have a common 
ancestor as they differ drastically in sequence and three-dimensional structure (Li, 2005).   
 
SH3 Domain Diversity 
SH3 domains are the most widespread proline-recognition domains in vertebrates 
with over 400 copies present in the human proteome.  This abundance is due to the wide 
variety of functions associated with SH3 domains (Li, 2005).  Human SH3 domain-
containing proteins are involved in processes surrounding actin cytoskeleton reorganization, 
endocytosis, signal transduction, and the regulation of apoptosis (Carducci et al., 2012).  A 
large number of SH3 domain-containing proteins fall into the category of adaptor/scaffolding 
proteins, which have a modular structure but no enzymatic activity.  They consist of multiple 
protein-protein and/or protein-lipid interacting domains, allowing for binding to other 
proteins, the plasma membrane, or intracellular organelles (Csiszar, 2006) 
 
SH3 Domain Structure 
SH3 domains are approximately 60 amino acids in length.  One study compared the 
sequence homology of 266 non-redundant SH3 domain sequences and found that any two 
sequences shared an average of 27% identity (Larson and Davidson, 2000).  This study also 
calculated the positional entropy for each of the 60 amino acid positions by identifying the 
frequency at which a specific amino acid was found at a site.  The study identified and 
ranked the 24 most conserved residues, each with a positional frequency of greater than 14% 
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(Figure 16).  The conserved residues of SH3 domains are known to be involved in 
maintaining the general structure of the domain and for binding its ligand (Larson and 
Davidson, 2000).   
 
 
SH3 domain structure consists of approximately 5 β-strands that are arranged in an 
anti-parallel formation to create two β-sheets.  The first sheet is comprised of β-strands 1, 2, 
and 5, while the second is made from β-strands 3 and 4.  This can be seen in a three-
dimensional model of the 5th SH3 domain of Tks5 (Figure 17).  The β-sheets are arranged at 
an approximate right angle to create a conserved β-barrel fold.  The β-strands are connected 
by three variable loops: the RT-loop, the n-Src loop, and the distal loop. (Carducci et al., 
2012).  A short 310 helix is located between β-strands 4 and 5.  The amino- and carboxy-
termini of the SH3 domain of Src are located in close proximity, which suggests that the 
domain could extend from the protein surface without disrupting the overall protein structure.  
This may also be true of other SH3 domain-containing proteins as modeled for Tks5 (Figure 
17) (Smithgall, 1995).  
Figure 16. SH3 Domain Sequence Homology.  The structural features of SH3 domains 
are noted above the amino acid sequences for the following proteins: p47-phox (C-terminal 
SH3), Tks5 (C-terminal SH3 #5), Src, Abl, and Crk (N-terminal SH3).  Twenty-four of the 
most conserved residues are highlighted according to their functions: ligand binding (light 
blue), hydrophobic core (yellow), structural (red), RT loop (grey), β-turn (green), β-sheet 
bend (purple).  The multiple sequence alignment was constructed using WebPRANK. 
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The dissociation constants of SH3 domains are generally weak (1-200 µM), and thus 
SH3 domains are less selective than some of the other proline-recognition subfamilies, which 
tend to have dissociation constants ranging from the high nM to low µM range (Li, 2005; 
Nguyen et al., 1998; Zarrinpar et al., 2003).  This low affinity can, on occasion, be 
advantageous to the cell as it allows for rapid turnover of signaling complexes.  One example 
of this is seen in focal adhesions during integrin signaling in which SH3 domain-containing 
protein complexes are formed transiently, thus allowing for the brief interactions with the 
ECM conducive for cell motility.    
As the low binding affinity allows for versatility in SH3 domain binding partners, it is 
difficult to predict specific interactions based on sequences alone.  A given SH3 domain 
could interact with multiple different ligands, though only a fraction of these might take 
Figure 17. SH3 Domain Structure. Structure of the 5th SH3 
domain of Tks5 adapted from NCBI Conserved Domain Database 
using Cn3D software.   
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place in vivo (Li, 2005).  One of the ways by which cells increase SH3 domain specificity is 
through compartmentalization of binding.  One example of this is CD2, a surface antigen that 
is expressed on all peripheral blood T cells.  The GYF domain of CD2BP2 (CD2 binding 
partner 2) binds to CD2 in the detergent soluble membrane fraction whereas the SH3 domain 
of Fyn tyrosine kinase binds CD2 in the same cells, but in lipid rafts (Li, 2005).  
Identification of the location of SH3 domain-containing proteins within a cell could thus help 
elucidate binding partners.  Specificity can also be achieved through multiple potential 
binding sites and/or multiple SH3 domains.  Although SH3 domain binding is weak, multiple 
contacts are made in the context of a folded protein.  These contacts mediate further 
interactions, thus enabling tighter binding to ligands.  Both the localization of SH3 domain 
containing proteins and their multiple sites of interaction make it less likely for the protein to 
diffuse away without rebinding at functional sites within the cell (Mayer and Eck, 1995).   
 
SH3 Domain Interactions 
An SH3 domain is able to bind to proline-rich sequences in other proteins due to two 
main grooves and a pocket located in succession on the domain surface formed by large, 
hydrophobic amino acids (Figure 18).  The two grooves have the ability to create hydrogen 
bonds and van der Waals interactions with the backbone of a left-handed helical structure 
formed by proline-rich peptides.  The pocket, referred to as the specificity pocket, binds to an 
arginine or lysine residue located adjacent to the proline-rich sequence to confer specificity 
and stronger binding.  
In a study of the ability of SH3 domains to bind various ligands, the majority of them 
appeared to recognize specific sequences dubbed class I and class II poly-proline motifs.  
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Class I ligands are characterized by the sequence (R/K)XΦPXΦP while class II ligands carry 
the sequence ΦPXΦPX(R/K) with ‘Φ’ representing any hydrophobic residue and ‘X’ 
representing any amino acid (Carducci et al., 2012).  The proline-rich motif is able to bind in 
two orientations (Li, 2005).  Class I ligands have the upstream arginine or lysine in the 
specificity pocket, while class II ligands have the downstream arginine or lysine in this site 
(Mayer and Eck, 1995) (Figure 18).  The majority of the SH3 domains that have been studied 
bind to class I and class II ligands with equal preference while some SH3 domains 
 Figure 18. SH3 Domain Binding to Class I and Class II Poly-proline Motifs.  
(A) Class I, (R/K)XΦPXΦP, and (B) class II ΦPXΦPX(R/K) poly-proline motifs 
bind in opposite orientations due to orientation of the arginine or lysine residue.  
Φ represents any hydrophobic residue and X represents any amino acid. 
	 46	
preferentially bind to one class over the other, although the reasoning behind preference has 
not yet been made clear (Carducci et al., 2012).  
In order for protein-protein binding to be possible, the interacting peptide sequence 
must be exposed to the solvent and be accessible to the binding partner.  Proline is the best 
amino acid for this function as these sequences are found at the surface of proteins.  Proline-
rich sequences are widely distributed in the proteome, including 25% of all proteins in 
humans (Carducci et al., 2012).  As proline-rich regions are common, it is important to 
establish rules regarding the binding of SH3 domains.  The five member ring of proline 
restricts the Φ torsional angle of the amino acid at approximately minus 60° thereby 
restricting the sequences containing prolines to a few specific conformations (Li, 2005) 
(Figure 19A).   
The class I and class II binding partners of SH3 domains adopt a structural feature 
called a left-handed poly-proline-II (PPII) helix.  This structure has average torsional angles 
of Φ = -75° and Ψ = +145° (Chebrek et al., 2014) (Figure 19B).  PPII helices contain a 
PXXP core comprised of two prolines on the same face of the helix separated by any two 
amino acids, with three residues per turn (Mayer and Eck, 1995).  The overall sequence is 
roughly triangular in cross section (Cohen et al., 1995; Mayer and Eck, 1995) (Figure 19B).  
Side chains and backbone carbonyls are projected outward, available for interaction.  It is not 
uncommon for ‘X’ to be additional prolines as it increases stabilization, however, the PPII 
helix is relatively stable and can resist several amino acid substitutions without changing the 
overall shape of the backbone (Li, 2005).   
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Figure 19. Structure of a Poly-Proline-II (PPII) Helix.  (A) Comparison of a 
generalized amino acid structure to the N-substituted proline structure.  Location 
of torsional angles and the bond conferring N-substitution are noted in grey.  (B) 
PPII helix structure, front and side views.  Constructed using six consecutive 
prolines and torsional angles of Φ = -75° and Ψ = +145° with Avogadro software.  
Bottom images show the backbone structures. 
	 48	
The feature of PPII helices that is recognized by SH3 domains is the irregular 
backbone substitution pattern.  The proline residues are N-substituted, meaning the nitrogen 
is bound to an atom besides the hydrogen and the Cα carbon found in the middle of an amino 
acid (Figure 19A).  These prolines are placed at key positions along the otherwise normal 
Cα-substituted peptide scaffold.  The Cα- and N-substituted residues are separated by one 
backbone carbon, allowing for them to fit into the SH3 domain’s binding grooves (Nguyen et 
al., 1998).  Prolines are required at these sites because they are the only naturally available 
N-substituted amino acids.  The requirement for N-substituted residues has been shown 
through replacement of proline with sarcosine, a non-natural N-substituted amino acid.  
These replacements are tolerated and still allow binding to SH3 domains because the N-
substitution is maintained (Nguyen et al., 1998). 
SH3 domain and ligand complexes have been studied using X-ray crystallography.  
The two main binding grooves are hydrophobic and are lined mainly by aromatic residues 
such as tryptophans, phenylalanines, and tyrosines.  These residues are characterized as 
having bulky side chains with planar, near-parallel structures that accommodate the PPII 
helix (Li, 2005).  Each groove has the potential to accommodate two residues, specifically 
the ‘ΦP’ dipeptide units at the base of the triangle (Li, 2005; Mayer and Eck, 1995) (Figure 
18; Figure 20).    
While the PXXP core is recognized by proline-recognition domains, this small area of 
interface creates a weak overall interaction (Li, 2005), and it does not explain the selectivity 
of SH3 domains for these ligands (Mayer and Eck, 1995).  The selectivity of SH3 domains 
must be mediated, in part, through the SH3 domain residues flanking the proline-rich regions 
as well as a third site, the negatively charged specificity pocket found in SH3 domains 
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(Mayer and Eck, 1995).  This pocket is located around the third and fourth β strands and is 
flanked by the far end of the second β strand, the n-Src loop, and the tip of the RT loop 
(Figure 20A).  This surface often contains more than one subpocket and therefore may be 
 
more accurately referred to as the specificity zone (Saksela and Permi, 2012).  The variability 
of the loops in sequence and structure is what confers binding specificity (Carducci et al., 
2012). The RT and n-Src loops face the ligand and mediate protein interactions with terminal 
positively charged residues such as arginine and lysine.  Conversely, the distal loop is located 
Figure 20. Modeling SH3 domain binding between Tks5 and ADAM12.  (A) Structure of 
Tks5 5th SH3 domain adapted from NCBI Conserved Domain Database using Cn3D software.  
(B) Side chains of the specific residues involved in binding the 5th SH3 domain of Tks5 to the 
poly-proline motif of ADAM12. Modeled using Cn3D and Avogadro software. The ADAM12 
poly-proline motif is represented by a grey ball and stick model.  The residues involved in 
binding are highlighted according to the binding site they reside in. (C) Sequence of Tks5 fifth 
SH3 domain with residues involved in binding highlighted: site 1 (yellow), site 2 (orange), and 
the site 3 specificity pocket (teal).  
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on the opposite face of the SH3 domain and may contact other regions of the interacting 
protein (Mayer and Eck, 1995).  
The positively charged arginine and lysine residues found in class I and class II poly-
proline motifs are thought to provide binding stability through ligand orientation and 
electrostatic interactions (Carducci et al., 2012).  For example, the arginine present in a class 
I sequence can form a salt bridge with the conserved acidic residue found in the specificity 
pocket of SH3 domains (Cohen et al., 1995; Mayer and Eck, 1995).  Since SH3 domains only 
bind weakly to PXXP core motifs, any mutation in a proline, arginine, or lysine residue 
within the sequence has the ability to disrupt binding.  Moreover, substitution of as few as 
two or three residues in the specificity pocket, while not necessarily changing the ability of 
the SH3 domain to bind poly-proline motifs, can easily alters its specificity (Li, 2005).   
 
Non-Consensus Ligands 
Some SH3 domains bind to other proteins in an atypical manner, such as in the case 
of the adaptor protein Grb2 and its regulation of the Vav guanine nucleotide exchange factor.  
In this case binding occurs between the C-terminal SH3 domain of Grb2 and the N-terminal 
SH3 domain of Vav, thus occurring through a complementary interface of both SH3 domains 
rather than through standard poly-proline motif binding (Li, 2005).  Additionally, some SH3 
domains bind non-consensus sequences. For example, the SH3 domain of Eps8 binds 
PXXDY, the SH3 domain of Fyn/Fyb binds RKXXYXXY, and the SH3 domain of Pex13p 
binds to an α helix formed by a WXXXFXXLE while simultaneously binding a conventional 
poly-proline motif on the opposite face (Li, 2005).  A characteristic feature of non-consensus 
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ligand binding is the extensive use of contacts with the SH3 specificity pocket (Saksela and 
Permi, 2012).   
In a more comprehensive study, some SH3 domains did not provide an interpretable 
binding pattern, suggesting the presence of uncharacterized non-consensus sequences 
(Carducci et al., 2012).  In addition, most of the SH3 domains in the human genome do not 
have a characterized ligand, which may skew the perception of consensus sequences and the 
prevalence of consensus binding (Saksela and Permi, 2012). 
 
SH3 Domain Prevalence in Cancer 
SH3 domain-containing adaptor proteins are common in signal transduction 
pathways.  The modular structure of adaptor proteins allows binding to multiple molecules 
simultaneously.  Signaling results in the transient formation of the large macromolecular 
assemblies capable of specifying the spatiotemporal features of signal transduction pathways 
(Cohen et al., 1995; Csiszar, 2006).  Different signaling events employ unique combinations 
of adaptors allowing for regulation of network assembly.  Additionally, cell type-specific 
receptors influence tissue-dependent outcomes.  The composition of adaptors at the entry 
sites of signals can determine whether the signal gets transmitted or degraded.  This 
combinatorial control allows for tight regulation of compartment specificity and duration of 
signals (Csiszar, 2006).   
SH3 domains can also relay phosphorylation signals.  Activation of signal 
transduction pathways can occur through open and closed conformations of adaptor proteins, 
which allows for liberation or masking of binding surfaces.  These conformational changes 
can be triggered by post-translational modifications (Csiszar, 2006).  One example of this is 
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seen in the NADPH oxidase, a protein complex responsible for superoxide production.  One 
component of the NADPH oxidase, p47phox, is held in a closed, inactive conformation 
through interactions between its C-terminal SH3 domain and its N-terminal PX domain, 
which contains a poly-proline motif within its primary sequence (Figure 21).  When inactive,  
 
 
the protein is unable to interact with its SH3 domain-binding partners and the lipid binding 
surface of the PX domain is masked.  The protein becomes activated when it is 
phosphorylated on serine residues in its polybasic region, presumably by PKC.  It is thought 
that the presence of the phosphate groups disrupts the electrostatic interaction network 
mediated by the acidic residues of the SH3 domain.  This disruption unfolds the protein and 
renders it accessible to its binding partners (Li, 2005).  It is likely that SH3 domain-
containing proteins commonly have both inactive, intramolecularly bound and active, 
binding-competent conformations (Mayer and Eck, 1995).  A similar mechanism may be 
employed by Tks5 (see Discussion). 
Figure 21. Activation of p47phox.  Inactive p47phox is characterized by intramolecular 
binding between a poly-proline motif within its PX domain and its C-terminal SH3 domain.  
Upon phosphorylation this binding is disrupted, resulting in an open, active conformation.  
This mechanism allows for transduction of phosphorylation signals through SH3 domain 
function.   
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SH3 domain-containing adaptor proteins function as hubs in signaling networks while 
regulating basic aspects of cellular organization through protein-protein interactions (Csiszar, 
2006; Thalappilly et al., 2008).  The important roles that SH3 domain-containing proteins 
play in signal transduction suggest they may be good therapeutic targets for cancer cells.  
 
SH3 Domain Targeting in Cancer Therapeutics 
 The issue with traditional cancer therapies such as chemotherapy is the lack of 
specificity.  In addition, the prevention of metastasis, the leading cause of death in cancer 
patients, is an aspect of cancer that has not been well addressed.  Identifying new targets in 
cancer signaling pathways is a promising approach to effective treatments for this disease.  
Inhibition of signaling could allow for cytostatic therapies rather than the widely used 
cytotoxic therapies, resulting in fewer side effects.  Some of these inhibitors could also target 
metastasis leading to a new avenue for cancer therapeutics (Vidal et al., 2001). 
SH3 domain-containing proteins have been shown to be essential in several signaling 
pathways leading to cell division, differentiation, and cytoskeletal reorganization in response 
to growth signals.   There is evidence of deregulation of some of these proteins in tumors, 
which could explain the malignant phenotypes seen in cancer cells (Vidal et al., 2001).  
According to a search using UniProt Knowledgebase, there are approximately 120 oncogenic 
human proteins that contain SH3 domains.  For these reasons, SH3 domains have attracted 
attention as potential targets for new anti-proliferative drugs (Smithgall, 1995). 
Interestingly enough, many SH3 domain-containing adaptor proteins are targets of 
caspases, proteases that shut off signal transduction during apoptosis.  Additionally, E3 
ubiquitin ligases can target proteins with SH3 domains to irreversibly downregulate signal 
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transduction activity through proteasomal degradation.  Therefore, targeting SH3 domains 
appears to be a feasible means of halting cell growth or invasion and should be able to have 
wide implications in cancer treatment (Csiszar, 2006).  
SH3 domain interactions have been analyzed in order to design agents with antitumor 
activity (Vidal et al., 2001).  The specificity pockets of SH3 domains are very complex and 
variable, which allows for more specific inhibition of SH3 domains of interest (Saksela and 
Permi, 2012).  In cancer cells, ligands designed around the sequences recognized by specific 
SH3 domains have shown promise in inhibiting signaling pathways that are constitutively 
activated by tyrosine kinases (Vidal et al., 2001).  The use of synthetic peptides based on 
natural target sequences has been effective in blocking ligand binding to SH3 domains.  
These inhibitors may have utility in controlling cancer-associated signaling pathways 
(Smithgall, 1995).   
 For example, activation of the small GTPase Ras is implicated in transmission of 
tyrosine kinase signaling for stimulation of cell proliferation (Smithgall, 1995).  Deregulation 
of Ras activity can result in cellular transformation.  Inhibitors of tyrosine kinases disrupt 
deregulated Ras signaling and show antitumor potential.  Within this Ras signaling pathway 
is the SH3 domain-containing protein Grb2 (Vidal et al., 2001).  As previously discussed, 
activation of a receptor tyrosine kinase creates binding sites for Grb2, bringing it to the 
plasma membrane (Figure 22).  The SH3 domain of Grb2 interacts with a poly-proline motif 
on Sos (Son of Sevenless), recruiting Sos to the plasma membrane and allowing it to be 
located in close proximity to Ras.  Sos has the ability to activate Ras (Smithgall, 1995).  Grb2 
is not oncogenic, however its overexpression has been shown to occur in breast cancer (Vidal 
et al., 2001).  For this reason, it has been studied as a potential target in this signaling 
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pathway without directly targeting Ras.  This avenue has shown some success, with 
dominant negative expression of Grb2 SH3 domain mutants effectively blocking mitogenic 
signaling (Tanaka et al., 1995).  In a similar study, dominant negative expression of Grb2 
with deletion of either one of its SH3 domains inhibited Grb2/Sos signaling complex  
 
  
formation and reversed transformation in cells.  In still another approach, the dominant 
negative expression of a Sos mutant containing only the poly-proline motif necessary for 
binding Grb2 resulted in the inability to create functional signaling complexes (Vidal et al., 
2001).  In a more recent study, a variety of small molecules were tested in a virtual screen for 
their abilities to inhibit the interaction between the C-terminal SH3 domain of Grb2 and the 
Figure 22. The Role of Grb2 in Ras Signaling.  The SH2 domain of Grb2 
binds to phosphorylated receptor tyrosine kinases.  The SH3 domains of Grb2 
are bound to Sos, recruiting it to the plasma membrane.  When in close 
proximity to Ras, Sos, as a guanine nucleotide exchange factor, is able to 
catalyze GTP/GDP exchange, resulting in Ras activation.     
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docking protein Gab2.  Some of the molecules tested were able to inhibit this interaction with 
moderate affinity, and the most promising candidates were based on a dihydro-s-triazine 
scaffold showing the possibility of inhibiting SH3 domain interactions without the use of 
poly-proline motifs or SH3 domain mutants (Simister et al., 2013).  These examples verify 
the successful targeting of the Grb2 SH3 domain, thus supporting the concept that SH3 
domains within other signal transduction pathways may be similarly targeted without having 
to inhibit kinase signaling pathways directly. 
Some SH3 domain inhibitors may specifically suppress the metastatic properties of 
cancer cells.  For example, the binding of the SH3 domain of cortactin to AMAP1, an Arf 
GTPase activating protein, is a potential therapeutic option.  Use of a cell-permeable peptide 
identical to the AMAP1 proline-rich region and designed to bind two cortactin molecules 
was effective in preventing this interaction.  This inhibitor decreased cancer cell invasion and 
metastasis without affecting cell viability (Hashimoto et al., 2006).   
As it might seem difficult to inhibit SH3 domain interactions due to their relatively 
low binding affinities, some studies have been more focused on designing inhibitors that are 
not identical to natural ligands in order to increase binding affinity.  Use of an inhibitor with 
increased binding affinity could more easily displace the natural ligand allowing for more 
effective inhibition of SH3 domain function (Vidal et al., 2001).  The development of poly-
proline motifs with non-natural N-substituted amino acids in the place of prolines has been 
shown to increase binding affinity to SH3 domains in some cases, suggesting a possible route 
for inhibitor design (Nguyen et al., 1998).  Another example of increasing binding affinity 
involved a Grb2 inhibitor that was synthesized to contain two linked proline-rich sequences.  
This approach resulted in the creation of a dimer with greater binding affinity than a single 
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motif.  The dimer bound to two Grb2 SH3 domains simultaneously, improving the disruption 
of the interaction between Grb2 and Sos and leading to effective inhibition of Ras activation 
(Cussac et al., 1999).   
Approaches similar to the aforementioned examples could be tested for their 
efficacies in suppressing Tks5 interactions and invadopodia-mediated invasion.  Each Tks5 
SH3 domain is structurally different, allowing for targeting of individual SH3 domains to 
disrupt the specific interactions necessary for these processes (Figure 23).  A potential 
drawback to SH3 domain targeting could be the inability of agents to discriminate between 
normal and cancerous cells.  However, through better understanding of the roles that SH3 
domains play within these pathways, any potential issues might be easily alleviated.  Use of 
correct doses may suppress tumor cell proliferation without completely inhibiting normal cell 
proliferation.  Additionally, normal cells respond to multiple pathways, so inhibition of a 
single pathway might not affect proliferation and differentiation (Smithgall, 1995).  
Targeting a specific SH3 domain function is a viable means of disrupting the unregulated 
proliferation and invasion signaling pathways in cancer cells without being detrimental to the 
processes necessary for normal cell signaling.  Further study of Tks5 SH3 domain function 
alongside testing of dominant negative expression of Tks5 SH3 mutants or small molecule 
inhibitors designed to displace ligands could provide a means of preventing cancer 
metastasis.   
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Figure 23. Structures of the five SH3 domains of Tks5.  (A) Sequence alignment of the SH3 
domains of Tks5.  Residues involved in binding are highlighted: site 1(yellow), site 2 (orange), 
and the site 3 specificity pocket (teal).  Sequence alignment constructed using WebPRANK.  (B) 
Tks5 SH3 domain structures, adapted from NCBI Conserved Domain Database using Cn3D 
software.  The solution structure for the third SH3 domain of Tks5 is not currently available.  The 
image shown was modeled using SWISS-MODEL structure homology software and adapted for 
Cn3D using VAST software.  
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Objectives 
Tks5 activation is accomplished through Src-mediated tyrosine phosphorylation, 
leading to Tks5 localization at the plasma membrane and binding of its PX domain to 
PI(3,4)P2.  Once at the plasma membrane, Tks5 has been shown to be instrumental to the 
assembly of invadopodia precursor complexes.  This activity by Tks5 is accomplished 
through its scaffolding function, as invadopodia-associated proteins are recruited to these 
sites by binding to the five SH3 domains of Tks5.     
While the importance of Tks5 in invadopodia formation has been investigated, not 
much is known about the specific roles that the individual SH3 domains of Tks5 play in these 
processes.  Additionally, there is little understanding of the mechanism by which Src 
phosphorylation leads to Tks5 activation.  Furthermore, the regulation of Tks5 SH3 domain 
interactions is poorly understood.  Better characterization of the SH3 domains of Tks5 might 
allow for identification of an interaction that could potentially be inhibited as a therapeutic 
option for metastatic disease.   
We hypothesize that the SH3 domains of Tks5 influence the development of 
invadopodia through alterations in Tks5 cellular localization and regulation of Tks5 
activation status.  We address this hypothesis through the following specific aims.  First, we 
will identify the specific SH3 domains of Tks5 that are necessary for ECM degradation 
associated with invadopodia formation.  Second, we will determine how Tks5 SH3 domain 
mutants affect the ability of Tks5 to be activated through phosphorylation by Src tyrosine 
kinase and/or conformational changes.  And third, we will examine the localization of these 
Tks5 SH3 domain mutants in invadopodia-competent cells.  Presumably the alterations we 
expect to see in matrix degradation, activation, and localization will depend on the proteins in 
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which Tks5 interacts, thus making an analysis of Tks5-protein interactions a long-term goal 
of this study as well. 
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Methods and Materials 
Construct Design and Verification 
In previous work in the Seals lab, murine Tks5 cDNAs had been introduced into the 
pSGT mammalian expression vector and point mutations created in each of the SH3 domains 
by site-directed mutagenesis such that the first tryptophan within a conserved pair was 
converted to an alanine (WW à AW).  This is a common strategy for interfering with the 
protein-binding properties of each SH3 domain, and was applied here in order to study the 
function of each SH3 domain in Tks5 (Nguyen et al., 1998; Li, 2005; Tanaka et al., 1995) 
(Table I and Figure 24).  In preparation for the studies in this thesis project, an experiment  
  
     Table I. Point Mutations in Tks5 Constructs 
 
     
 
 
 
    *Position of mutations based on  
    short form of Tks5 
 
was undertaken to compare the expression of Tks5 from the pSGT vector, which uses an 
SV40 promoter, and the pcDNA3 vector, which uses a CMV promoter.  The expression of  
  
Tks5 
Construct 
Mutation* 
M1 W188A 
M2 W260A 
M3 W441A 
M4 W827A 
M5 W1056A 
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ectopic Tks5 based on the expression vector was compared following immunoblotting 
(Figure 25).  The results of this experiment indicated far more robust Tks5 expression from 
the pcDNA3 vector.  We therefore decided to alter the wild-type version of Tks5 in pcDNA3 
Figure 24. Inactivation of Tks5 SH3 domains.  (A) Amino acid alignment of Tks5 SH3 
domains.  Yellow: conserved; blue: mostly conserved; red: tryptophan mutated to an alanine.  
(B) Schematic representation of Tks5 showing location of inactivating SH3 domain point 
mutations for the constructs used in this study. 
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to create four new constructs (M1-M4) harboring the SH3 domain point mutations described 
above.  This was accomplished by replacing the regions surrounding each SH3 domain in the  
 
 
 
pcDNA3 vector with the mutant form previously created in the pSGT vector.  The M5 
construct had already been cloned into the pcDNA3 vector long before this thesis project.  
Large-scale preparations of wild-type and mutant DNA constructs were generated (Qiagen, 
ThermoFisher) and the mutations confirmed by DNA sequencing (GeneWiz).     
 
Cell Culture 
The human prostate carcinoma cell line called LNCaP was cultured at 37°C and 5% 
CO2 in RPMI-1640 media (Hyclone) formulated with 2 mM L-glutamine, 10 mM HEPES, 
Figure 25. Immunoblot analysis of Tks5 expression based 
on expression vector.  LNCaP cells were transfected with 
wild-type Tks5 constructs made in pSGT or pcDNA3 
mammalian expression vectors.  Lysates were subjected to 
immunoblotting for Tks5 to compare protein expression 
levels.  GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase) served as a loading control. 
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and 100 mg/L sodium pyruvate, and supplemented to a final concentration of 10% fetal 
bovine serum (Sigma-Aldrich) and 1% penicillin/streptomycin (Hyclone). 
Src-transformed fibroblasts (Src-3T3 cells), COS-7 cells, and HEK293 cells were 
cultured at 37°C and 5% CO2 in DMEM media (Sigma-Aldrich) formulated with 110 mg/L 
sodium pyruvate and 2 mM L-glutamine, and supplemented to a final concentration of 10% 
fetal bovine serum and 1% penicillin/streptomycin.  
 
Nucleofection/Electroporation 
Each Tks5 construct was individually introduced into LNCaP cells according to 
previously defined protocols by NucleofectionTM (Lonza), a proprietary electroporation 
technique (Burger et al., 2014).  Briefly, 2 x 106 LNCaP cells were mixed with 3-10 µg of 
plasmid DNA and solutions from Nucleofector Kit R to a final volume of 100 µL.  
Nucleofection was carried out using program T-009.  After nucleofection, cells were allowed 
to recover for 15-30 minutes in 500 µL of pre-warmed media before being plated for further 
experimentation as defined below.  Cells nucleofected with wild-type Tks5 and with an 
empty pcDNA3 vector served as positive and negative controls, respectively. 
 
Lipid-based Transfections 
Approximately 2 x 106 cells were seeded in 6-cm dishes.  At 70% confluency, the 
cells were transfected with Tks5 constructs in the pcDNA3 vector, Src Y527F in the pSGT 
vector, and/or the PX domain of Tks5 in the pEGFP-N1 vector using LipofectamineTM 3000 
reagent (ThermoFisher) according to manufacturer protocol.  Briefly, two separate 250 µL 
aliquots of Opti-MEM® reduced serum media (ThermoFisher) were mixed with 3.75 µL and 
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7.5 µL Lipofectamine 3000, respectively.  A 500 µL aliquot of Opti-MEM was mixed with 
10 µL P3000TM reagent and 7 µg plasmids.  The 500 µL aliquot was then split between the 
tubes containing Lipofectamine 3000 and incubated at room temperature for 10 minutes.  
Both aliquots were then added to cells in 6-cm dishes, and then the cells were incubated 48 
hours at 37°C. 
 
Invadopodia Activity 
LNCaP cells were grown at 37°C in a 12-well plate with approximately 3.2 x 105 
cells per well.  Each well contained a glass coverslip coated with poly-L-lysine (50 µg/mL) 
and Oregon Green 488-labeled gelatin (111 µg/mL), a denatured form of the extracellular 
matrix protein collagen, as previously described (Martin et al., 2012).  After 48 hours, the 
cells on the coverslips were fixed with 0.3% formaldehyde, permeabilized with 0.4% Triton 
X-100, stained with AlexaFluor 594-conjugated phalloidin (1:200; Invitrogen) and 5% 
donkey serum/PBS, and mounted using small aliquots of ProLongTM Gold Antifade 
Mountant with DAPI (Life Technologies).  Using an Olympus BX51 microscope (OPELCO) 
equipped with a Retiga EXi Fast 1394 camera (QImaging), ten random images were 
collected for each experimental condition with each image containing an average of 30 cells.  
Image processing was conducted with Q-Capture 64 Suite software.  The area of gelatin 
degradation was quantified using ImageJ 1.49 software for each image and then normalized 
based on the number of cells within each image.  
Transfected Src-3T3 cells were allowed to recover for 24-48 hours before being lifted 
and re-plated into 12-well plates containing the same kind of poly-L-lysine/Oregon Green 
488-labeled gelatin coated coverslips as mentioned above.  Four hours after plating cells, the 
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coverslips were fixed and stained for Tks5 as described in the Invadopodia Localization 
section of the Methods and Materials.  Quantification of gelatin degradation was carried out 
using a 100X objective and Type F Immersion Oil (Olympus). 
 
Cell Lysates 
During the cell lysis procedure, all plates and buffers were kept on ice.  Cultured cells 
were washed twice with 0.6 volumes of 1 mM sodium orthovanadate in PBS, then lysed 
using 0.05 volumes of NP40 lysis buffer composed of 20mM Hepes, 110 mM sodium 
chloride, 40 mM sodium fluoride, 1% NP40, 1 mM sodium orthovanadate, 10 µg/mL 
aprotinin, 10 µg/mL benzamidine, 10 µg/mL leupeptin, 10 µg/mL pepstatin, and 1 mM 
PMSF.   The cells were scraped from the dish, incubated on ice for 10 minutes, and the 
cellular debris removed by centrifugation at 10,000 x g for 10 minutes at 4°C.  Total protein 
was determined using a detergent-compatible protein assay kit according to manufacturer 
protocol (Bio-Rad), and by measuring absorbance at 750 nm on a SpectraMax Pro 
(Molecular Devices) relative to known BSA standards.  
 
SDS-PAGE/Immunoblotting 
For immunoblotting, 35 to 55 µg of whole cell lysate protein were first loaded on a 
denaturing 7.5% polyacrylamide gel, separated at 150-200 V for approximately 1 hour, and 
then transferred to a 0.45 µm nitrocellulose membrane (Bio-Rad).  After blocking in 5% 
milk/0.5% BSA in 0.1% PBST, the membrane was incubated overnight at 4°C with a 
primary antibody specific to Tks5 (1:1000; #sc-30122; Santa Cruz), phosphotyrosine 
(1:1000; Clone 4G10; Millipore), GFP (1:1000; sc-9996; Santa Cruz), c-Myc (1:1000; clone 
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4A6; Millipore), HA (1:1000; clone 12CA5; Roche Life Science), phospho-Src Y416 
(1:1000; #2101; Cell Signaling Technology), or GAPDH (1:1000; #sc-25778; Santa Cruz) in 
10% blocking buffer.  This was followed by incubation in a species-specific peroxidase-
conjugated secondary antibody (1:2500; NA9340V; NA931V; GE Healthcare, Piscataway, 
NJ) for 30 minutes at room temperature.  Proteins were visualized using Western Lightning 
Plus Chemiluminescence reagent (PerkinElmer) or SuperSignalTM West Dura Extended 
Duration Substrate (ThermoFisher Scientific) and a ChemiDoc imaging system (Bio-Rad).  
Expression was quantified using Image LabTM Software 5.1 (Bio-Rad).   
 
Immunoprecipitation 
Cells were lysed and protein was quantified as described previously.  Lysates 
containing 200-500 µg protein were then diluted to a final volume of 500 µL using NP40 
lysis buffer.  One microliter of a Tks5 polyclonal antibody (1736.9; reactive to the 4th SH3 
domain of Tks5), 5 µL c-Myc antibody (clone 4A6; Millipore), or 2 µL GFP antibody (sc-
9996; Santa Cruz) were added to each sample and mixed on a rotator at 4°C for 2 hours.  
Antibodies bound to their target proteins were then separated from unbound proteins by 
mixing with 10 µL protein A-conjugated Sepharose 4G beads (#101041; Life Technologies) 
or immobilized protein G beads (#30399; Pierce) on a rotator at 4°C for 1 hour.  Beads were 
then washed three times in 500 µL of NP40 lysis buffer by addition, centrifugation at 1000 x 
g for 1 min at 4°C, and removal of the supernatant.  Precipitated proteins were eluted from 
the beads with 50 µL SDS-PAGE gel loading buffer containing DTT by boiling for 5 minutes 
at 95°C.  Precipitated proteins were separated using SDS-PAGE and visualized by 
immunoblotting as described above for Tks5, phosphotyrosine, or GFP detection.  
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Invadopodia Localization 
 Untagged Tks5 constructs (wild-type, M1-M5) in the pcDNA3 vector, carboxy 
terminal, Myc-tagged Tks5 constructs in the pSGT vector, and/or the FYVE domain of Hrs 
in the pEGFP vector were introduced into cells.  Coverslips were transferred to a 12-well 
plate for processing at 48 hours after transfection.  The coverslips were fixed with 0.3% 
formaldehyde, permeabilized with 0.4% Triton X-100, and incubated with a primary 
antibody specific to the Myc tag (1:1000; clone 4A6; Millipore) in 5% donkey serum/PBS 
for three hours. The coverslips were then incubated for one hour with the appropriate 
fluorescent-conjugated secondary antibody (1:2000; AlexaFluor 488-anti-mouse; GE 
Healthcare) and AlexaFluor 594-conjugated phalloidin (1:200; Invitrogen) to visualize Myc-
tagged Tks5 and F-actin, respectively.  When studying co-localization, coverslips were 
incubated with primary antibodies to Tks5 (1:1000; #sc-30122; Santa Cruz), EEA1 (1:1000; 
#610456; BD Transduction LabsTM), total Src (1:1000; #2108; Cell Signaling), or cortactin 
(1:1000; #05-180; Millipore) in 5% donkey serum/PBS for three hours.  The coverslips were 
then incubated for one hour with the appropriate fluorescent-conjugated secondary antibodies 
(1:2000; AlexaFluor 488-anti-rabbit; GE Healthcare) (1:2000; AlexaFluor 594-anti-mouse; 
GE Healthcare).  Coverslips were mounted using small aliquots of ProLongTM Gold Antifade 
Mountant with DAPI and imaged as described above.  Oil immersion microscopy was carried 
out for LNCaP localization and Src-3T3 co-localization imaging as described above, using a 
100X objective and Type F Immersion Oil (Olympus).  
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Bioinformatic Procedures 
Retrieval	of	Human	Proteins	
	 A	list	of	human	proteins	containing	SH3	domains	was	compiled	using	the	
UniProt	Knowledge	Base	(http://www.uniprot.org/).		Briefly,	an	advanced	search	was	
carried	out	for	“SH3”	using	the	domain	search	and	“Homo	sapiens”	using	the	organism	
search.		This	resulted	in	a	list	of	220	proteins	in	this	knowledge	base	to	be	used	for	
further	analysis.			
	
Retrieval	of	Domain	Sequences	
	 PX	and	SH3	domain	sequences	were	obtained	from	the	NCBI	Protein	Database	
(http://www.ncbi.nlm.nih.gov/protein/).		Searches	were	carried	out	using	UniProt	
entry	identifiers	in	order	to	access	information	pages	specific	to	the	proteins	of	interest.		
Under	the	“Features”	section,	regions	containing	the	PX	domain	and	SH3	domain	
sequences	were	identified.		Selecting	regions	allowed	for	highlighting	of	the	domain	
sequence	of	interest	in	the	sequence	located	under	the	“Origin”	section.		These	
sequences	were	transferred	to	a	document	and	translated	to	FASTA	format	for	further	
analysis.			
	
Multiple	Sequence	Alignment	
	 Multiple	sequence	alignments	were	formulated	using	webPRANK	
(http://www.ebi.ac.uk/goldman-srv/webprank/),	Clustal	Omega	
(http://www.ebi.ac.uk/Tools/msa/clustalo/),	and	MUSCLE	
(http://www.ebi.ac.uk/Tools/msa/muscle/).		Default	parameters	were	used	for	each	
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program.		Sequences	of	interest	were	submitted	in	FASTA	format	and	each	program	
aligned	the	sequences	and	produced	distance	trees	showing	sequence	similarity.			
	
Poly-proline	Motif	Scan	
	 PX	domain	sequences	were	scanned	for	poly-proline	motifs	using	ScanProsite	
(http://prosite.expasy.org/scanprosite/).		“Option	3”	was	selected	in	order	to	search	
known	domain	sequences	for	a	motif	of	interest.		The	sequences	were	entered	in	FASTA	
format.		Common	poly-proline	motifs	were	searched	against	these	sequences,	
specifically	(K/R)xxPxxP,	PxxPx(R/K),	and	RxxK.			
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Results 
Tks5 SH3 Domain Mutations Result in Differential Effects on ECM Degradation in 
LNCaP Cells 
Previous research has shown that the introduction of ectopic Tks5 into LNCaP cells, a 
cell line largely deficient in this protein, can induce invadopodia development and 
invadopodia-associated gelatin degradation activity (Burger et al., 2014).  We wanted to 
determine the role of Tks5 SH3 domain mutations in invadopodia development using this 
model system.  This was accomplished using Tks5 constructs with SH3 domain mutations 
(WW à AW) that would be expected to disrupt the binding of Tks5 to other proteins at these 
sites.  To that end, we introduced wild-type or mutant Tks5 from the pcDNA3 mammalian 
expression vector into LNCaP cells to comparable expression levels with GAPDH serving as 
a gel loading control (Figure 26A).  The nucleofected cells were also grown on coverslips 
coated with fluorescently-labeled gelatin in order to determine the extent of matrix-degrading 
invadopodia activity in these cells (Figures 26B and 26C).  In this assay, matrix degradation 
is seen as cleared zones (‘holes’) in the fluorescent gelatin monolayer with the average 
degradation per cell represented in terms of a fold-change in activity relative to wild-type 
Tks5.  Our results showed surprising differential changes in invadopodia activity exerted by 
the Tks5 mutants.  Disruption of the 4th or 5th SH3 domain of Tks5 (M4-W827A, M5-
W1056A) resulted in what appeared to be a slight decrease in the ability of the cells to 
degrade gelatin relative to wild-type (WT) Tks5.  Conversely, disruption of the 1st (M1-
W188A), 2nd (M2-W260A), or 3rd (M3-W441A) SH3 domain resulted in a 2.5- to 4-fold 
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increase in gelatin degradation.  We speculated at the time that these results may reflect 
either a down-regulatory control mechanism exerted on Tks5 by other proteins that bind to 
these domains, an increased ability to be activated by Src phosphorylation including potential 
Tks5 conformational changes, or an increase in translocation of Tks5 to invadopodia when 
these first three SH3 domains are disrupted.  
  
Tks5 SH3 Domain Mutants Are Uniformly Distributed in LNCaP Cells 
Tks5 has been shown to localize to punctate invadopodia formed by LNCaP cells, 
though in the past this depended on the stable overexpression of Tks5 (Burger et al., 2014).  
Figure 26. Effects of Tks5 SH3 Domain Mutations on Invadopodia-associated Gelatin 
Degradation by LNCaP cells.  (A) Nucleofected LNCaP cells expressing wild-type (WT) Tks5 or 
Tks5 mutants (M1-M5) were analyzed for Tks5 and GAPDH protein levels in total cell lysates by 
immunoblotting.  (B) Representative images taken at 40X magnification showing gelatin 
degradation in the nucleofected LNCaP cells. (C) Quantification of gelatin degradation area per 
cell.  Error bars represent standard error.  
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In order to investigate the hypothesis that the localization of the transiently expressed Tks5 
mutants plays a role in the observed differences in degradation ability, the mutants were 
again introduced into LNCaP cells by nucleofection and this time the cells were transferred 
to uncoated glass coverslips.  After 48 hours, the coverslips were fixed and stained for actin 
and Tks5 (Figure 27).  Interestingly, no overt differences were observed in the distribution of 
Tks5 within these cells.  That is, the LNCaP cells transiently nucleofected with Tks5, unlike 
the Tks5 overexpressing stable LNCaP cell line, all had a similar morphology and did not 
form any obvious actin-rich invadopodial structures, despite their ability to degrade gelatin in 
an invadopodia-like manner (Figure 27).  This is consistent with previous observations 
(Burger et al., 2014), and suggests that Tks5 localization did not likely play a role in the 
degradation ability of these cells.  In sum, the localization of Tks5 mutants within the cells 
and the appearance of the cells themselves did not vary between any of the tested conditions 
leading us to explore other hypotheses beyond the enhanced ability to localize to 
invadopodial structures. 
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Figure 27. Effects of SH3 domain mutations on Tks5 localization in LNCaP cells.  
Representative images show localization of nuclei (blue), F-actin (red), and Tks5 (green) 48 
hours post-nucleofection of LNCaP cells by fluorescent microscopy. Images were taken at 
100X magnification.  
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COS-7 Cells as a Model for Investigations Surrounding Tks5 SH3 Domain Mutations 
Previous studies have shown that Tks5 activity within a cell is directly linked to the 
ability of Tks5 to be phosphorylated by Src tyrosine kinase (Burger et al., 2014).  Mutation 
of Y557 and Y619 result in a diminished ability of Tks5 to be phosphorylated by Src.  And 
introduction of these mutants into LNCaP cells results in a significantly diminished ability of 
the cells to degrade gelatin (Burger et al., 2014).  It could be speculated that any disruption in 
the binding of proteins to any of the first three SH3 domains of Tks5 could allow for easier 
access to these tyrosine residues by Src, and thus allow for increased phosphorylation and 
Tks5 activity.  We thus hypothesized that the ability of these Tks5 SH3 domain mutants to be 
phosphorylated within the LNCaP cells may be affecting their ability to degrade gelatin 
films. 
 In order to detect Tks5 phosphorylation, LNCaP cells were nucleofected with Tks5 
and constitutively active Src Y527F constructs.  Whole cell lysates were subject to 
immunoprecipitation using an antibody specific to Tks5 and then analyzed for tyrosine 
phosphorylation by immunoblotting with a phosphotyrosine-specific antibody.  Both Tks5 
and activated Src, monitored with an antibody that detected Src phosphorylation at Y416 (p-
Src), were detectable in the transiently nucleofected LNCaP cells.  However, detection of 
Tks5 phosphorylation proved more difficult with this cell line despite past screens with the 
assay being successful (Burger et al., 2014).   
To potentially remedy the situation, we turned to COS-7 cells as they are a relatively 
easier cell line to transfect (Figure 28).  Relative to LNCaP cells, COS-7 cells showed 
detectable tyrosine phosphorylation of Tks5 and were therefore adopted for analysis of Tks5 
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SH3 domain mutant phosphorylation studies.  To that end, Tks5 SH3 domain mutants were 
introduced into COS-7 cells alongside Src Y527F and after 48 hours were analyzed for 
tyrosine phosphorylation (Figure 29).  Unfortunately, difficulties arose with this assay, as 
some transfections appeared to be toxic to the COS-7 cells producing undetectable levels of 
Src and Tks5 expression.  When phosphorylation was detectable, all Tks5 SH3 domain 
mutants appeared to have the capacity to be phosphorylated by Src, however the results 
overall were largely inconclusive.  Due to inability to effectively assess tyrosine 
phosphorylation or to detect any changes in phosphorylation as a result of SH3 domain 
mutations, this hypothesis was not pursued further.  
Figure 28. Detection of Tks5 phosphorylation in 
LNCaP and COS-7 cells.  The top panel depicts 
the total cell lysates (input) from LNCaP and COS-
7 cells transiently expressing Tks5 and Src Y527F 
based on immunoblot analysis with antibodies to 
Tks5 and p-Src.  The lower panel depicts the 
lysates following immunoprecipitation (IP) with a 
Tks5 antibody and analyzed for either Tks5 or Tks5 
tyrosine phosphorylation (pY) by immunoblot 
analysis.  
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 COS-7 cells were also explored for their use as a model system for Tks5 mutant 
localization, cell morphology, and matrix degradation.  In this case, COS-7 cells were 
transiently transfected with wild-type Tks5, constitutively active Src Y527F, or both 
constructs.  Cells were then grown on glass coverslips or coverslips coated with Oregon 
Green 488 gelatin for 48 hours (Figure 30).  COS-7 cells transiently expressing Src Y527F 
and wild-type Tks5 appeared to develop invadopodia-like structures (Figure 30A).  These 
structures remained largely punctate with coincident staining of Src, Tks5, and F-actin, 
though some cells acquired the ability to form more developed crescent- or ring-shaped 
invadopodial structures as well.  COS-7 cells transiently expressing Src Y527F alone also 
appeared to have the ability to form actin-based invadopodial structures, so while the 
formation of invadopodia by COS-7 cells appears to be Src-dependent, it may or may not be 
Tks5-dependent depending on the endogenous Tks5 protein levels in this cell line (Figure 
30A).  Despite the morphological changes to the transfected COS-7 cells, none of them 
Figure 29. Effects of Tks5 SH3 domain mutations on Tks5 tyrosine phosphorylation in 
COS-7 cells co-expressing Src Y527F.  Input lysates from transiently transfected COS-7 
cells were analyzed for Tks5 and p-Src by immunoblot analysis.  Lysates were also 
immunoprecipitated (IP) with a Tks5 antibody and analyzed for Tks5 and Tks5 tyrosine 
phosphorylation (pY) by immunoblot analysis.   
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Figure 30. Morphology (A) and matrix degradation (B) by COS-7 cells transiently 
expressing wild-type Tks5, Src Y527F, or both constructs.  Images were taken at 40X 
magnification by fluorescent microscopy using antibodies for Tks5 and Src as well as 
phalloidin for F-actin.  The arrow points to an invadopodia-like structure in a cell transfected 
with both Tks5 and Src Y527F.  
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appeared to acquire the ability to degrade gelatin in ways seen previously for LNCaP cells, so 
the ultimate use of this cell line for studies of matrix degradation did not seem feasible 
(Figure 30B).  Previous work with COS-7 cells had also alluded to the inability of this cell 
line to degrade matrix (Crowley et al., 2009).    
 Due to the formation of actin-rich structures in COS-7 cells co-expressing of Src 
Y527F and Tks5, further studies were carried out to investigate the morphology of COS-7 
cells co-expressing Src Y527F and the Tks5 SH3 domain mutants (Figure 31).  While the 
cells continued to form actin-rich structures, no overt differences were observed based on 
Tks5 SH3 domain mutation.  It is likely that Src Y527F alone is sufficient to induce these 
morphological changes, and when combined with the lack of matrix degradation in this cell 
line, it was decided that the COS-7 model system would no longer be utilized for 
experimentation. 
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Figure 31. Morphology of COS-7 cells co-expressing Src Y527F and Tks5 SH3 domain 
mutants.  COS-7 cells were transiently transfected with Src Y527F and Tks5 SH3 domain 
mutants (M1-M5) and then analyzed by fluorescent microscopy using antibodies for the 
detection of Tks5 and Src alone with phalloidin for F-actin.  The arrows point to invadopodia-
like structures in the merged images.  Images were taken at 40X magnification.     
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Tks5 SH3 Domain Mutations Affect Tks5 Localization and Invadopodia Formation in 
Src-3T3 Cells  
 Use of the LNCaP and COS-7 cell lines was unable to provide any conclusive results 
regarding Tks5 localization and cell morphology.  In order to better investigate these aspects 
of Tks5 function, we began experimentation with Src-3T3 cells.  Src-3T3 cells carry stable 
expression of a constitutively active form of Src and thus develop robust invadopodia in the 
form of superstructures called “rosettes”.  Src-3T3 cells also have high levels of endogenous 
Tks5, and Tks5 localizes to these rosettes (Seals et al., 2005).  Mutants carrying a Myc 
epitope tag were introduced into these cells to provide easy detection of transiently 
expressed, ectopic Tks5 using a Myc antibody.  This was done to determine the effects of 
these mutations on cell morphology were explored alongside the localization of Tks5 mutants 
relative to invadopodia.  Src-3T3 cells were transfected with the Tks5 mutants, and stained 
for actin and Tks5-Myc 48 hours post-transfection (Figure 32).  Based on the results in 
LNCaP cells (Figure 26) we hypothesized that that Tks5 harboring mutations in the first 
(M1), second (M2), or third (M3) SH3 domains might exhibit robust localization to 
invadopodia, but instead these mutant constructs resulted in nearly a complete loss in 
invadopodia formation.  Additionally, these mutants appeared to aggregate in the cytoplasm 
in the region surrounding the nucleus.  In contrast, the Tks5 harboring mutations in the fourth 
(M4) and fifth (M5) SH3 domains did not appear to affect invadopodia formation, and these 
mutants were further able to localize to rosettes to the same extent as wild-type Tks5.   
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Figure 32. Effects of Tks5 SH3 domain mutations on Src-3T3 cell morphology and Tks5 
localization. Src-3T3 cells were transiently transfected with wild-type (WT) Tks5 of Tks5 SH3 
domain mutants (M1-M5) and then analyzed for morphology and Tks5 localization by fluorescent 
microscopy.  Ectopic Tks5 was monitored with an antibody to the Myc epitope.  Representative 
images show localization of nuclei (blue), actin (red), and the Myc epitope of Tks5 (green) 48 
hours post-transfection. Closed arrows point to rosette-shaped invadopodia structures.  Open 
arrows point to mis-localized M1, M2, and M3 Tks5 constructs to peri-nuclear aggregates. Images 
were taken at 40X magnification.    
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Tks5 SH3 Domain Mutations Affect ECM Degradation Efficiency by Src-3T3 Cells 
 Using the LNCaP model, the M1, M2, and M3 mutant Tks5 constructs result in an 
increase in invadopodia-associated matrix degradation activity, however they obliterate 
invadopodia integrity in Src-3T3 cells.  Additionally, the aggregates formed by these mutants 
in Src-3T3 cells did not co-localize with actin, suggesting that the F-actin that did exist did 
not possess the ability to degrade matrix proteins.  To test this hypothesis, Src-3T3 cells 
expressing Tks5 SH3 domain mutants were analyzed for their ability to degrade gelatin films.  
Tks5 mutants were introduced into Src-3T3 cells, and 48 hours post-transfection the cells 
were lifted and re-plated onto Oregon Green 488 gelatin coated coverslips for an additional 4 
hours, after which the cells were fixed and stained for Tks5-Myc (Figure 34).  In some cases, 
the cells expressing M1, M2, or M3 Tks5 mutants appeared to lose their ability to degrade 
gelatin in the shorter time frame of this assay.  For those cells that retained some ability to 
degrade gelatin, the degradation pattern appeared to lack focalization, occurring diffusely 
underneath the entire span of the cell in a pattern similar to that exhibited by LNCaP cells 
transiently expressing Tks5 (Figure 26B).  This was contrary to the degradation patterns 
made by Src-3T3 cells expressing wild-type Tks5, or the M4 or M5 Tks5 mutants, which all 
showed more focalized gelatin degradation at sites of invadopodia formation (Figure 33).  By 
focusing matrix degradation where it is needed, more efficient invasion may be maintained 
(Mukhopadhyay et al., 2009).  Loss of invadopodia formation thus appeared to impair the 
ability of these cells to efficiently degrade matrix through a loss of focalized gelatin 
degradation. 
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Figure 33. Effects of Tks5 SH3 domain mutations on invadopodia-mediated gelatin 
degradation by Src-3T3 cells. Src-3T3 cells were transiently transfected with wild-type (WT) 
Tks5 or Tks5 SH3 domain mutants (M1-M5) and then analyzed for gelatin degradation by 
fluorescent microscopy.  Ectopic Tks5 in transfected cells was monitored with an antibody to the 
Myc epitope. Representative images show nuclei (blue), the Myc epitope tag of Tks5 (red), and 
gelatin (green) after a 4 hour degradation period. Arrows point to focalized sites of degradation. 
Images were taken at 100X magnification.  
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It is noteworthy that the nonspecific gelatin degradation patterns observed in LNCaP 
cells transiently expressing Tks5 (Figure 26) was similar to that of Src-3T3 cells expressing 
M1, M2, or M3 Tks5 SH3 domain mutants (Figure 33).  It is possible that these diffuse 
gelatin degradation patterns represent some sort of comprise in the ability to fully focalize 
gelatin degradation in ways seen in cells fully competent for invadopodia formation.  It is 
possible that LNCaP cells lack all the requisite components for focalized matrix degradation, 
whereas the Src-3T3 cells, which have them, become compromised in their functionality, 
thus leading to more inefficient invadopodia-associated matrix degradation patterns.  
 
Tks5 Constructs with M1-M3 Mutations Co-localize with Early Endosome Markers in 
Src-3T3 Cells  
We noted that the aggregates formed by the M1, M2, and M3 mutant Tks5 constructs 
were highly reminiscent of the punctate distribution of the isolated PX domain of Tks5 when 
introduced into normal NIH3T3 fibroblasts (Abram et al., 2003).  As the PX domain of Tks5 
is used for lipid interactions, it was hypothesized that the isolated PX domain was associated 
with early endosomes which are rich in PI(3)P (Abram et al., 2003).  We further 
hypothesized that the PX domain of Tks5 might also be responsible for localizing the M1, 
M2, and M3 Tks5 mutants to endosomes. In order to determine the nature of the aggregates 
formed by these Tks5 mutants, Src-3T3 cells were transfected with each Tks5 SH3 domain 
mutant construct and 48 hours post-transfection were stained for the Myc epitope of Tks5 
and for early endosomal antigen 1 (EEA1), a protein with a lipid-binding FYVE domain that 
is often used as an early endosomal marker (Stenmark et al., 1996) (Figure 34).  As  
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Figure 34. Localization of Tks5 SH3 domain mutants and EEA1 in Src-3T3 cells.   
Src-3T3 cells were transiently transfected with wild-type (WT) Tks5 or Tks5 SH3 domain 
mutants (M1-M5) and then analyzed for Tks5 and EEA1 localization by fluorescent microscopy.  
Ectopic Tks5 in transfected cells was monitored with an antibody to the Myc epitope. 
Representative images show localization of nuclei (blue), Tks5 (green), and EEA1 (red) 48 
hours post-transfection.  Closed arrows point to invadopodia rosettes.  Open arrows point to 
endosomes.  Images were taken at 100X magnification. 
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anticipated, each of the M1, M2, and M3 mutations created a version of Tks5 that co-
localized with EEA1, suggesting that these mutants may be mis-localizing due to interactions 
between the PX domain and endosomal membranes, thus resulting in the aggregates 
observed in the previous experiment (Figure 32).   
In order to confirm these results, the localization pattern of the lipid-binding FYVE 
domain of the early endosomal protein Hrs was also compared with the Tks5 SH3 domain 
mutants in Src-3T3 cells (Figure 35).  Consistent with the previous results, the FYVE domain 
co-localized with the M1, M2, and M3 mutant Tks5 constructs at organelles patterned similar 
to that of endosomes.  This suggests that by disrupting the protein-binding capacity of the 1st, 
2nd, or 3rd SH3 domains, the full-length Tks5 protein is able to interact with these subcellular 
structures.  As the FYVE domain of Hrs is responsible for localizing the protein through 
interactions with phosphoinositides, it appears possible that the PX domain of Tks5 in each 
of these mutants is ultimately responsible for the localization to and quite possibly the 
exaggerated formation of endosomes within these cells.  
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Figure 35. Localization of the FYVE domain of Hrs and Tks5 SH3 domain mutants in Src-
3T3 cells.  Src-3T3 cells were transiently transfected with wild-type (WT) Tks5 or Tks5 SH3 
domain mutants (M1-M5) along with the FYVE domain of Hrs tagged with GFP before being 
analyzed by fluorescent microscopy.  Ectopic Tks5 in transfected cells was monitored with an 
antibody to the Myc epitope. Representative images show localization of nuclei (blue), Tks5-
Myc (green), and the FYVE domain of Hrs (red) 48 hours post-transfection.  Closed arrows point 
to invadopodia rosettes.  Open arrows point to endosomes. Images were taken at 100X 
magnification.   
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Mutations in the First, Second, and Third SH3 Domains of Tks5 Mis-localize Src in 
Src-3T3 Cells 
 The invadopodia formed by Src-3T3 cells have been shown to be dependent on Tks5 
expression, as silencing of Tks5 in these cells leads to invadopodia disassembly and a loss in 
gelatin degradation (Seals et al., 2005).  Src-3T3 cells expressing the M1, M2, and M3 
mutant Tks5 constructs exhibit a more diffuse gelatin degradation pattern that might be 
explained by the localization of Tks5 to early endosomes.  However, these cells still express 
endogenous Tks5, which should be able to function normally in driving invadopodia 
formation.  For this reason, it was hypothesized that the loss of invadopodia formation and 
more diffuse gelatin degradation pattern could be due to mis-localization of invadopodia-
associated Tks5 binding partners to these organelles.  In order to test this hypothesis, we first 
tested the potential co-localization of these Tks5 mutants with the Tks5 binding partner 
cortactin.  The fifth SH3 domain had been previously shown to mediate biding between Tks5 
and cortactin at the invadopodia-related podosomes of vascular smooth muscle cells 
(Crimaldi et al., 2009).  In invadopodia-competent Src-3T3 cells expressing wild-type, M4, 
or M5 Tks5 constructs, both Tks5 and cortactin localized to invadopodia (Figure 36).  
However, while the M1, M2, and M3 Tks5 constructs still localized to endosomes, cortactin 
did not appear to strongly co-localize with these mutants and remained largely cytoplasmic 
with some sporadic localization at edges of the plasma membrane.  This may be explained by 
the fact that in a recent study, cortactin was shown to localize to sites of invadopodia  
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Figure 36. Localization of Tks5 SH3 domain mutants and cortactin in Src-3T3 cells. Src-
3T3 cells were transiently transfected with wild-type (WT) Tks5 or Tks5 SH3 domain mutants 
(M1-M5) and then analyzed for Tks5 and cortactin localization by fluorescence microscopy. 
Ectopic Tks5 in transfected cells was monitored with an antibody to the Myc epitope. 
Representative images show localization of nuclei (blue), Tks5-Myc (green), and cortactin 
(red) 48 hours post-transfection. Closed arrows point to Tks5 and cortactin co-localization at 
invadopodia rosettes.  Open arrows point to mis-localized M1, M2, and M3 constructs without 
cortactin co-localization. Images were taken at 100X magnification. 
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formation prior to Tks5.  Thus cortactin localization was not be affected by the localization 
of these Tks5 mutants (Sharma et al., 2013).    
 As Src is responsible for the activation of many invadopodial proteins and for 
invadopodia formation (Boateng and Huttenlocher, 2012), the localization of Src was also 
studied in Src-3T3 cells expressing the M1, M2, and M3 mutant Tks5 constructs.  Like 
cortactin before, wild-type Tks5 and the M4 and M5 Tks5 mutants all co-localized with Src 
at invadopodia (Figure 37).  However, unlike cortactin, Src also co-localized with the M1, 
M2, and M3 Tks5 mutants at endosomal structures. Since Src was mis-localized in these 
cells, invadopodia-associated Src substrates may be unable to be activated at the plasma 
membrane, thus providing a possible explanation for the loss of invadopodia formation.  
 Previous research has demonstrated that inactive Src co-localizes with endosomal 
markers in the perinuclear region (Sandilands and Frame, 2008).  Src is then delivered 
through endosomal trafficking to the plasma membrane for activation by receptor tyrosine 
kinases.  Disruption of endosomal trafficking machinery results in an inability of Src to be 
translocated to the plasma membrane, and, therefore, Src is retained at cytoplasmic 
endosomes (Sandilands and Frame, 2008).  Since a similar phenotype was seen in this study 
with the introduction of M1, M2, or M3 mutant Tks5 constructs in Src-3T3 cells, it is 
possible that Tks5 regulates Src trafficking.  Thus, the mis-localization of Tks5 away from 
the plasma membrane may disrupt targeting of Src to the plasma membrane, resulting in 
sequestration of the kinase in cytoplasmic endosomes.  
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Figure 37. Co-localization of Tks5 SH3 domain mutants and Src in Src-3T3 cells.  Src-3T3 
cells were transiently transfected with wild-type (WT) Tks5 or Tks5 SH3 domain mutants (M1-
M5) and then analyzed for Tks5 and Src localization by fluorescence microscopy. Ectopic Tks5 
in transfected cells was monitored with an antibody to the Myc epitope. Representative images 
show nuclei (blue), Tks5-Myc (green), and total Src (red) 48 hours post-transfection. Closed 
arrows point to Tks5 and Src co-localization at invadopodia rosettes.  Open arrows point to mis-
localized M1, M2, and M3 constructs with Src co-localization. Images were taken at 100X 
magnification.  
	 94	
SH3 Domains Hold Tks5 in an Inactive Masked Conformation  
 Since the M1, M2, and M3 mutant Tks5 constructs localize to phosphoinositide-rich 
endosomes, it appears that these forms of Tks5 have a PX domain that is more accessible to 
interacting with endosomal membranes. Interactions within or between Tks5 molecules have 
been proposed in the past.  Tks5 has been suggested to have a closed intramolecular 
conformation that masks the PX domain until the protein is properly localized at sites of 
active Src at the plasma membrane (Abram et al., 2003).  More recently, a Tks5 dimer was 
proposed that might also keep the PX domain from promiscuous lipid-binding within the cell 
(Oikawa et al., 2012).  In order to distinguish between these two models, it is useful to 
compare Tks5 sequences to well-characterized proteins.   
In order to compare the SH3 domains of Tks5 to other well-characterized SH3 
domains, a search was carried out using the UniProt Knowledge and NCBI Protein Databases 
to identify the 220 human proteins with SH3 domains and 283 unique SH3 domain sequences 
(Table II). The sequences for the total 283 SH3 domains were aligned using Clustal Omega,  
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Table II. Human proteins containing SH3 domains. Listed by mnemonic identifier of UniProtKB 
entry.  The identifier for Tks5 is noted in red.  
ABI1 ASPP1 CSKI2 MYO1E ITSN2* MPP5 OBSCN RHG32 SH3G3 SPT13 UBS3B 
ABI2 ASPP2 CSKP ES8L3 JIP1 MPP6 OSTF1 RHG33 SH3K1
* 
SPTA1 VAV* 
ABI3 BAIP2 DBNL FBP1L JIP2 MPP7 OTOR RHG42 SH3R1* SPTN1 VAV2* 
ABL1 BCAR1 DESP FCSD1
* 
KALRN* MY15B P85A RIM3A
* 
SH3R2* SRBS1* VAV3* 
ABL2 BI2L1 DLG1 FCSD2
* 
LASP1 MYO15 P85B RIM3B
* 
SH3R3* SRBS2* VINEX
* 
ACK1 BI2L2 DLG2 FGR LCK MYO7A PACN1 RIM3C
* 
SH3Y1 SRC8 YES 
AHI1 BIN1 DLG3 FNBP1 LYN MYO7B* PACN2 RIMB1
* 
SHAN1 SRC ZO1 
AMPH BLK DLG4 FRK M3K9 NCF1* PACN3 RIMB2
* 
SHAN2 SRGP1 ZO2 
ANM2 BTK DLG5 FUT8 M3K10 NCF1B* PEX13 RUSC1 SHAN3 SRGP2 ZO3 
ARH37*  CACB1 DNMBP
* 
FYB M3K11 NCF1C* PLCG1 RUSC2 SHLB1 SRGP3 MYO1F 
ARH38 * CACB2 DOCK1 FYN M3KL4 NCF2* PLCG2 S3TC1 SHLB2 SRMS  
ARHG4 CACB3 DOCK2 GAS7 MACC1 NCF4 PPIP1 S3TC2 SKAP1 STAC  
ARHG5 CACB4 DOCK3 GRAP* MACF1 NCK1* PRAM SAMN1 SKAP2 STAC2  
ARHG6 CASL DOCK4 GRAP2
* 
MATK NCK2* PTK6 SASH1 SLAP1 STAC3
* 
 
ARHG7 CASS4 DOCK5 GRAPL MCF2L NEBL RASA1 SASH3 SLAP2 STAM1  
ARHG9 CD2AP
* 
DYST GRB2* MIA NEBU RHG04 SGSM3 SNX18 STAM2  
ARHGG CIP4 EFS HCK MIA2 NGEF RHG09 SH319* SNX33 TEC  
ARHGJ CRK* EM55 HCLS1 MIA3 NOSTN RHG10 SH321 SNX9 TNK1  
ARHGQ CRKL* EPS8 IASPP MPP2 NOXA1 RHG12 SH3B4 SPD2A
* 
TRIO*  
ASAP1 CSK ES8L1 ITK MPP3 NOXO1* RHG26 SH3G1 SPD2B
* 
TXK  
ASAP2 CSKI1 ES8L2 ITSN1* MPP4 NPHP1 RHG27 SH3G2 SPN90 UBS3A  
*Contains multiple SH3 domains 
 
 
MUSCLE, and WebPRANK.  Results from multiple programs were compared in order to 
ensure accuracy.  Distance trees were constructed by these programs for the 283 SH3 domain 
sequences, and are depicted, in part, in Figure 38.  For each of these programs, the sequences 
for the five SH3 domains of Tks5 were consistently grouped with the four SH3 domains of 
Tks4 and the two SH3 domains of neutrophil cytosol factor 1 (p47-phox).  This consistent 
grouping suggests that the structures of the SH3 domains present in these proteins are related.  
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The domain architecture of these proteins containing the most similar SH3 domains to 
Tks5 was investigated using NCBI Conserved Domain Database (Figure 39).  The domain 
architecture comparison demonstrated that each of these proteins contains an amino-terminal 
PX domain in addition to the SH3 domains.   
 
 
Figure 38. Subset of SH3 domain multiple sequence alignments containing the five SH3 
domains of Tks5. Alignments are based on the Clustal Omega, MUSCLE, and WebPRANK 
databases as shown.  
	
Figure 39. Domain architecture of Tks5, Tks4, and p47-phox.  Adapted from NCBI 
Conserved Domain Database.   
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In order to investigate the significance of the PX domain in the structure of these SH3 
domain-containing proteins, other human proteins containing SH3 domains and PX domains 
were identified.  The 220 human proteins identified as containing SH3 domains (Table 1I) 
were searched for PX domains by using the NCBI Protein Database.  This resulted in 
identification of 12 human proteins containing at least one SH3 domain and a PX domain 
(Table III).  The sequences for these PX domains were retrieved using the NCBI Protein  
 
Table III. SH3 domain containing human proteins with a PX domain. Listed by mnemonic 
identifier of UniProtKB entry.  
NCF1C NCF4 RHG33 SNX9 
NCF1 NOXO1 SNX18 SPD2A 
NCF1B RHG32 SNX33 SPD2B 
 
 
Database and aligned using Clustal Omega, MUSCLE, and WebPRANK.  Distance trees 
were constructed by each program in order to identify similarities in sequence (Figure 40).  
Again, the distance trees produced by these programs consistently resulted in grouping of 
Tks5, Tks4, and p47-phox.  The PX domain structure similarity suggests a similarity in the 
domain architecture of these proteins, with quite possibly similar functional implications. 
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Following the identification of sequence similarities between the SH3 domains and 
PX domains of Tks5, Tks4, and p47-phox, the binding properties of the characterized 
domains were investigated.  As the Tks4 SH3 domain interactions remain relatively 
uncharacterized, the SH3 domain interactions of p47-phox were focused on for this 
investigation.  p47-phox is a component of the NADPH oxidase, an enzyme complex 
responsible for superoxide production during phagocytosis (Ago et al., 2003).  p47-phox is 
known to exist in two conformations (Figure 21).  The inactive conformation is formed when 
a poly-proline motif in the N-terminal PX domain of p47-phox is bound to its C-terminal 
SH3 domain.  This renders both the PX and SH3 domains inaccessible and inhibits the 
Figure 40. PX domain multiple sequence alignments for SH3 domain-containing proteins.  
Highlighted are the groupings containing Tks5, Tks4, and p47-phox.  
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function of p47-phox.  However, three serine residues on the C-terminal end of the protein 
can be phosphorylated by protein kinases in order to induce a conformational change in p47-
phox.  This allows for the PX domain to disassociate from the SH3 domain, the PX domain 
to bind phosphoinositides, and the protein to be relocated to the plasma membrane where it is 
catalytically active (Ago et al., 2003).   
In order to investigate whether a similar, inactive conformation might exist for Tks5, 
the PX domain was scanned for poly-proline motifs, sequences allowing for binding to an 
SH3 domain (Table IV).  The PX domain of Tks5 contains a Class I poly-proline motif 
similar in position and sequence to those found in the PX domains of p47-phox and Tks4.   
 
Table IV.  Poly-proline motifs located in PX domains.  
Poly-proline Motif Protein Sequence Position in PX 
Domain 
RxxPxxP (Class I) NCF1C RiiPhlP 46-52 
NCF1 RiiPhlP 67-73 
NCF1B RiiPhlP 71-77 
SHPD2A RiiPflP 67-73 
SHPD2B RiiPflP 67-73 
PxxPxK (Class II) NCF4 PtlPaK 69-74 
SNX18 PhlPeK 58-63 
SNX33 PhlPeK 58-63 
SNX9 PslPdK 59-64 
SHPD2A PflPgK 70-75 
SHPD2B PflPgK 70-75 
 
In addition, the poly-proline motif identified in p47-phox is the motif used to bind the PX 
domain to the SH3 domain (Hiroaki et al., 2001) (Figure 41).  These results suggest that the 
structural similarity between Tks5 and p47-phox may lend itself to functional similarity.  As 
p47-phox undergoes an intramolecular interaction due to its structure, it may also be true that 
an SH3 domain of Tks5 may have the ability to bind its own PX domain.   
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In order to confirm these results, an amino acid sequence alignment was carried out 
by WebPRANK using the PX domain sequences of Tks5, Tks4, and p47-phox (Figure 42).   
The alignment further confirmed the sequence and location similarity of the poly-proline 
motif located in the PX domains of these proteins.  This suggests that this motif is important 
for protein function.  As the poly-proline motif found in p47-phox is important for the  
 
intramolecular interaction forming its inactive conformation, it is possible that an SH3 
domain of Tks5 may function in binding the PX domain to hold the protein in an inactive 
conformation (Figure 43).  This inactive conformation would model the similarities in PX 
domain and SH3 domain structure between Tks5 and p47-phox.  This inactive conformation 
may also be adopted by Tks4, which shares these structural similarities. 
>gi|325511390|sp|P14598.3|NCF1_HUMAN  
MGDTFIRHIALLGFEKRFVPSQHYVYMFLVKWQDLSEKVVYRRFTEIYEFHKTLKEMFPIEAGA
INPENRIIPHLPAPKWFDGQRAAENRQGTLTEYCGTLMSLPTKISRCPHLLDFFKVRPDDLKLP
TDNQTKKPETYLMPKDGKSTATDITGPIILQTYRAIANYEKTSGSEMALSTGDVVEVVEKSESG
WWFCQMKAKRGWIPASFLEPLDSPDETEDPEPNYAGEPYVAIKAYTAVEGDEVSLLEGEAVEVI
HKLLDGWWVIRKDDVTGYFPSMYLQKSGQDVSQAQRQIKRGAPPRRSSIRNAHSIHQRSRKRLS
QDAYRRNSVRFLQQRRRQARPGPQSPGSPLEEERQTQRSKPQPAVPPRPSADLILNRCSESTKR
KLASAV	
Figure 41. Amino acid sequence of p47-phox.  Poly-proline motif required for PX domain 
interaction with the C-terminal SH3 domain is highlighted in yellow.   
	
Figure 42.  PX domain sequence alignment of Tks5, Tks4, and p47-phox. Sequence containing 
poly-proline motif is shown (encompassing amino acids 60-103).  Highlighted residues represent a 
conserved poly-proline motif known to be important for p47-phox intramolecular binding.   
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 Tks5 contains three tyrosine residues downstream of its third SH3 domain, which are 
known to be phosphorylated by Src tyrosine kinase during Tks5 activation (Burger et al., 
2014).  Phosphorylation of these tyrosine residues may result in a conformational change 
reminiscent to that of p47-phox on its three serine residues located downstream of its C-
terminal SH3 domain.  Based on this observation, it is proposed that the intramolecular 
binding that Tks5 exhibits in this model takes place between the PX domain and the third 
SH3 domain.  
 In order to validate this model, further experimentation will need to be done.  Binding 
assays, specifically GST pull down assays and co-immunoprecipitation assays, can be 
implemented to address the possible interaction between the PX domain and the third SH3 
domain of Tks5.  Preliminary studies using co-immunoprecipitation assays have been carried 
Figure 43. Proposed Tks5 inactive conformation model.  In this model, Tks5 remains in an 
inactive conformation with its third SH3 domain bound to the poly-proline motif present in its 
PX domain.  When phosphorylated by Src tyrosine kinase on the three tyrosine residues 
located in close proximity to this SH3 domain, the protein undergoes a conformational change.  
This allows for dissociation of the PX domain and an open, active conformation.  
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out and provide promising results regarding the efficacies of binding assays in providing 
evidence of this interaction (see Future Directions).   
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Discussion 
Conclusions 
 In this study, inactivating point mutations were introduced into each of the SH3 
domains of Tks5 to study the role that each individual SH3 domain of Tks5 plays in 
invadopodia development and activity.  We identified the first, second, and third SH3 
domains of Tks5 as being instrumental to the regulation of its activity within the cell.  
Disrupting binding to these SH3 domains allowed for a 2.5- to 4-fold increase in matrix 
degradation in LNCaP cells.  However, in Src-3T3 cells there was a mis-localization of Tks5 
to intracellular structures and co-localization with endosome marker proteins leading to a loss 
of invadopodia formation and focalized degradation.  In the Src-3T3 cells expressing the M1, 
M2, or M3 mutant Tks5 constructs, Src was unable to be properly delivered to the plasma 
membrane, instead being retained at the same perinuclear endosome structures as Tks5.  This 
observation may explain the loss of invadopodia in these cells. Mechanistically, the presence 
of a poly-proline motif in the PX domain of Tks5 may confer binding to one of its own SH3 
domains, suggesting a possible intramolecular or intermolecular interaction that governs 
Tks5 activity, invadopodia development, and the invasive phenotype of cancer cells.   
  
Tks5 Inactive Conformation Model Pertaining to Model Cell Lines 
The existence of an interaction between the PX domain and the 3rd SH3 domain of 
Tks5 could provide an explanation for the results observed in this study.  The LNCaP cells 
have little Tks5 or active Src expression (Burger et al., 2014).  Any Tks5 that is introduced 
into these cells may be activated when in close proximity to the basal levels of PI(3,4)P2 
and/or Src at the plasma membrane, thus allowing for Tks5 phosphorylation, lipid binding, 
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and an opening of the protein’s structure (Sharma et al., 2013).  Once bound, Tks5 may 
function to recruit other invadopodia-associated proteins to the plasma membrane, thus 
allowing for the low and diffuse levels of matrix degradation observed by LNCaP cells 
transiently expressing Tks5 (Burger et al., 2014).  Mutations in any of the first three SH3 
domains of Tks5 could disrupt the intramolecular binding that masks the PX domain, thus 
allowing for increased binding of Tks5 to phosphoinositides at the plasma membrane and an 
increase in the observed matrix degradation (Figure 44).  Interestingly, LNCaP cells stably 
 
  
Figure 44.  Inactive conformation model in LNCaP cells. 
The Tks5 M1, M2, and M3 SH3 domain mutants have a PX 
domain that is accessible for lipid binding, thus allowing for 
enhanced matrix degradation activity within the cells.  Wild-
type (WT) Tks5 and the Tks5 M4 and M5 mutants have a 
PX domain that is only made available for interaction upon 
close proximity to the plasma membrane, where Src is 
localized.  However, since activated Src levels are relatively 
low, there is less overall Tks5 activity and matrix 
degradation.  
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expressing Tks5 have been shown to form punctate invadopodia that are capable of focalized 
degradation (Burger et al., 2014).  It is possible then that, over longer periods of time, 
LNCaP cells transiently expressing Tks5 might also be able to adjust to efficiently form 
mature invadopodial structures.   
 Src-3T3 cells have high levels of Tks5 and activated Src is expressed constitutively.  
Disrupted binding to any of the first three SH3 domains of Tks5 led to the accumulation of 
Tks5 in aggregates near the nucleus and without degradative capabilities.  These aggregates 
were reminiscent of the punctate staining of the isolated PX domain of Tks5 in normal NIH-
3T3 fibroblasts (Abram et al., 2003).  As the PX domain of Tks5 is known to bind to PI(3)P, 
a lipid found extensively at endosomes, the mutants were studied for co-localization with 
early endosomal markers.  Indeed, both EEA1 and the lipid-binding FYVE domain of Hrs 
seemed to partially co-localize at the aggregates, suggesting that the Tks5 M1, M2, and M3 
mutant constructs localize to these organelles.  It is possible that disrupted binding to these 
first three SH3 domains of Tks5 allows for an open conformation.  In unmasking the PX 
domain, Tks5 is available for promiscuous binding to phosphoinositide-rich organelles like 
endosomes (Figure 45).  In contrast, wild-type Tks5 and the Tks5 M4 and M5 mutant 
constructs localize correctly as they maintain a closed conformation until in close proximity 
to active Src.  Once phosphorylated, conformational changes allow for unfolding of Tks5 and 
its proper localization to the plasma membrane via its lipid-binding PX domain.  This 
provides a mechanism for how Src phosphorylation leads to Tks5 activity.   
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Figure 45. Proposed model for endosomal mis-localization of Tks5 M1, M2, and M3.  The 
M1-M3 mutations of Tks5 have an exposed PX domain that is available for promiscuous binding.  
Wild-type (WT) Tks5 and the M4 and M5 Tks5 mutants have a masked PX domain that is not 
available for lipid binding until activated by Src at the plasma membrane.  
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Src-3T3 cells are also known to create robust invadopodia in the form of super-
structures termed rosettes.  However, expression of the M1, M2, or M3 Tks5 mutants had a 
dominant-negative effect on invadopodia formation.  And while the cells still maintained the 
ability to degrade, the degradation pattern was no longer focused.  Additionally, Src co-
localized with the Tks5 M1, M2, or M3 mutant constructs at endosomal compartments.  Src 
is known to be delivered to invadopodia through endosomal trafficking (Figure 46).  And  
 
 
Figure 46. Endosomal trafficking of Src tyrosine kinase in an invadopod.  Src is delivered 
to invadopodia through endosomal trafficking.  Inactive Src is internalized through 
endocytosis where it may be recycled for redelivery to these sites. Motor proteins (red), Rabs 
(teal), the exocyst complex (dark blue), and SNARE proteins (black squiggly lines) are 
involved in trafficking Src through use of microtubules (large blue lines).  
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disruption of trafficking machinery (e.g., with Rab mutants) results in the retention of Src at 
endosomes within the cell (Sandilands and Frame, 2008).  A study done in MDA-MB-231 
cells also showed that an inhibition of SNARE trafficking machinery, specifically syntaxin13 
and SNAP23, resulted in a decrease in the number of invadopodia formed by these cells as 
well as in the amount of Src found at the plasma membrane (Williams and Coppolino, 2014).  
Also, when observing focal adhesions in HeLa cells and fibroblasts, depletion of the 
endocytic regulatory protein MICAL-L1 resulted in a loss of active Src at focal adhesions 
and a decrease in cell migration (Reinecke et al., 2014).  These studies suggest that a 
disruption in Src endosomal trafficking machinery may impair the ability of cells to form 
invadopodia, much as was observed here. 
As this phenotype was observed in cells expressing the M1, M2, or M3 Tks5 SH3 
domain mutations, it is possible that Tks5 is involved in endosomal trafficking of Src (Figure 
47). In support of this, the adaptor protein Tks4, the closest homolog to Tks5, has been 
shown to be involved in the delivery of MT1-MMP to invadopodia, though the precise 
mechanism behind this is unknown (Buschman et al., 2009).  Interestingly, there is evidence 
that Tks5 can bind to endosomal trafficking machinery, such as the kinesin Eg5 (Stylli et al., 
2009) (Figure 8B).  Evidence has also been found of Tks5 interacting with myosin light 
polypeptide 6, a subunit of myosin, myosin regulatory light chain 2, and the microtubule 
subunit tubulin (Stylli et al., 2009) (Figure 8).  Microtubules provide a mechanical scaffold 
for protein sorting, while motor proteins allow for movement of cargo across the 
cytoskeleton (Murray and Wolkoff, 2003).  Kinesins are known to bind microtubules and 
hydrolyze ATP to produce movement of cargo, including vesicles.  Myosins are actin-
associated motor proteins, some of which are also known to drive vesicle transport along 
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Figure 47. Proposed model for the role of Tks5 in Src delivery to the 
plasma membrane.  Tks5 appears to play a role in targeting Src vesicle 
delivery to sites of invadopodia formation. Tks5 has been shown to interact 
with motor proteins (red) and microtubules (large blue lines).  Other trafficking 
machinery includes Rabs (teal), the exocyst complex (dark blue), and SNARE 
proteins (black squiggly line).  
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microtubules (Murray and Wolkoff, 2003).  For these reasons, it remains possible that Tks5 
may play a role in the motor protein driven vesicular trafficking of Src and potentially other 
invadopodial proteins.  When Tks5 is mis-localized to phosphoinositide-rich organelles, this 
trafficking system appears to be disrupted and Src is unable to be properly delivered to the 
plasma membrane, resulting in a loss of invadopodia formation (Figure 48). 
 
 
  
This new model of Tks5 may provide better understanding of how Tks5 is regulated 
within cells.  Tks5 may exist in a closed conformation with an inaccessible PX domain until 
in close proximity to Src.  Once phosphorylated by Src, conformational changes allow for 
opening of the Tks5 structure and for normal Tks5 functioning within the cell.  One of these 
Figure 48. Tks5 inactive conformation in Src-3T3 cells.  Wild-type (WT) Tks5 and the M4 and 
M5 Tks5 mutants are activated upon close proximity to active Src at the plasma membrane where 
they may function in the targeting delivery of Src-containing vesicles to sites of invadopodia 
formation.  The Tks5 M1, M2, and M3 mutants, however, have an open conformation and a 
promiscuous PX domain capable of binding to endosomes.  As Tks5 is no longer at the plasma 
membrane, Src delivery is also disrupted and invadopodia are unable to be formed.  
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functions may be in the endosomal trafficking of Src to invadopodia.  In this way, Tks5 may 
function both upstream and downstream of Src allowing for a positive feedback loop in 
invadopodia development and maturation.   
 
Tks5 Function in Tumor Growth 
Understanding the regulation of Tks5 may have further applications outside of cancer 
cell invasion.  Tks5 has been shown in several studies to play a role in tumor growth.  For 
example, Tks5 silencing has been shown to decrease total cellular ROS in Src-transformed 
fibroblasts and SCC61head and neck cancer cells.  The protein p22-phox, a component of the 
NADPH oxidase, was shown to associate with full length Tks5as well as with a truncated 
“PX-SH3A-SH3B” version of Tks5, suggesting this association may allow for Tks5 
regulation of ROS production (Figure 8B) (Diaz et al., 2009).   
Tks5 silencing in MDA-MB-231 cells has also been shown to impair primary tumor 
growth in a mouse model through both an increase in apoptosis and a decrease in 
proliferation.  The authors also noted that when the cells lacking Tks5 were introduced 
directly into circulation, metastatic growth in the lungs was inhibited.  The tumors lacking 
Tks5 expression were hypoxic and associated with thin, leaky blood vessels, possibly 
accounting for the decrease in tumor size, however the mechanisms behind this are still 
largely unknown (Blouw et al., 2015).   
The 5th SH3 domain of Tks5 has been shown to interact with the N-terminus of 
XB130, an adaptor protein linked with BEAS-2B human bronchial epithelial cell growth, 
survival, and migration (Figure 8A).  Tks5 and XB130 also appear to form a complex with 
Src.  This particular interaction seems to play a role in cell proliferation and survival, 
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specifically in regulation of the G1 (resting) phase checkpoint.  Downregulation of XB130 
and Tks5 resulted in a decrease in Src activation, suggesting a possible mechanism for the 
effect of this interaction on proliferation (Moodley et al., 2015).  Interestingly, this study 
concluded that Tks5 may play a role upstream of Src activation, and this is consistent with 
our findings here.  It may be that the XB130 and Tks5 interaction mediate the vesicle 
trafficking of Src to the plasma membrane.  
 
Non-cancer Tks5 Function 
Further understanding of the regulation of Tks5 may have application in normal 
cellular function as well.  For example, Tks5 has been shown to be a key component of 
podosomes.  Podosomes are proteolytic structures similar to invadopodia but found in 
normal, but often professionally invasive, cell types, including osteoclasts, macrophages, 
endothelial cells, and vascular smooth muscle cells (Courtneidge et al., 2005).  
 Osteoclasts, the cells that resorb the bone matrix, organize podosomes in a 
superstructure called the “sealing zone” in order to carry out this function.  Tks5 has been 
shown to be essential for osteoclast podosome formation as well as podosome-mediated 
osteoclast fusion downstream of a signaling pathway regulated by TGF-β, PI3K, and Src.  
This process was also shown to mediate the fusion of osteoclasts with cancer cells, possibly 
allowing for immune system evasion in sites of bone metastases.  Binding partners of Tks5 in 
osteoclasts include the actin-binding gelsolin precursor protein, actin-regulating filamin-A, a 
homolog of the transcriptional activator flightless 1, the actin capping protein tropomodulin3, 
the actin-plasma membrane linker protein moesin, and cofilin.  Interestingly, Tks5ΔPX was 
also able to bind to the actin-plasma membrane linker protein radixin, Abl interactor 1 
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(Abi1), WIP, WASp family member 2 (WAVE2), WASp itself, Grb2, and filamin-B (Figure 
8B) (Oikawa et al., 2012).   
 Macrophages form podosomes in order to navigate the ECM of various tissues and 
remove microorganisms and debris from the body.  Tks5 has also been shown to be 
necessary for proper function of these structures through regulation of adhesion, motility, 
ECM degradation, and MMP expression and activity (Burger et al., 2011).  Similar to 
osteoclasts, cancer cell-macrophage hybrids have been found in vivo and may contribute to 
the ability of cancer cells to escape immune surveillance (Oikawa et al., 2013).   
Aortic endothelial cells and vascular smooth muscle cells also form podosomes in 
order to invade tissues during angiogenesis (Gimona et al., 2003; Varon et al., 2006).  
Similarly, myoblasts form podosomes to develop muscle.  Tks5 and β-dystroglycan, a 
ubiquitous transmembrane laminin-binding protein, are known to localize at these structures 
in myoblasts.  A dystroglycan-Src complex was found to bind to the 3rd SH3 domain of Tks5 
within these cells (Figure 8A) (Thompson et al., 2008).   
The Src-Tks5 signaling pathway has also been shown to be necessary during 
embryonic development.  Zebrafish one-cell stage embryos were injected with morpholinos 
designed to suppress Tks5 expression.  At 48 hours post fertilization, these embryos were 
unable to fully develop and displayed small heads, small eyes, edema around the heart, and a 
delay in pigment cell appearance in their tails.  These defects were attributed to faulty 
migration of neural crest cells, multipotent cells that arise from the embryonic ectoderm.  
Further investigation demonstrated that TGF-β stimulation of murine neural crest stem cells 
leads to Src and Tks5 activation as well as podosome formation (Murphy et al., 2011).   
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The role of Tks5 in development was further investigated in a mouse model.  
Homozygous disruption of the gene was carried out through insertion of a trapping cassette 
containing a transcriptional termination sequence between exons 1 and 2 of the SH3PXD2A 
gene, a method known as “gene-trapping.”  This technique resulted in neonatal death and a 
cleft palate.  It was hypothesized that interference with cell migration affected palatogenesis 
(Cejudo-Martin et al., 2014).   
  Tks5 is also known to play a role in diseases outside of cancer.  For example, Tks5 
phosphorylation has been found to be associated with Alzheimer’s disease.  Alzheimer’s is 
caused by amyloid-β peptide accumulation leading to neuronal death.  Tks5 appears to be 
involved in this neurotoxic signaling by amyloid-β.  Furthermore, Tks5 associated 
neurotoxicity has been shown to be ADAM12 dependent.  Disruption of Tks5 and ADAM12 
activity enables protection against amyloid-β induced cell death (Malinin et al., 2005).  
 Finally, Tks5 has been shown to be recruited to enteropathogenic Escherichia coli 
(EPEC) infection sites.  EPEC secrete effector proteins into the underlying intestinal lumen 
to trigger formation of podosome-like structures referred to as pedestals.  The pedestals 
facilitate attachment of the bacteria to the intestinal lumen.  Tks5 localization to these areas 
was recently discovered, though pedestals are still able to be formed by intestinal cells 
expressing Tks5ΔPX.  Thus, the significance of Tks5 to these processes remains unknown 
(Jensen et al., 2015).  
 
 
 
 
	 115	
Future Directions 
Validation of Tks5 Closed Conformation through SH3 Domain Interactions with PX 
Domain 
In order to address possible inactive conformations of Tks5, the ability of the SH3 
domains of Tks5 to bind to its PX domain can be tested through GST pull down assays.  
Briefly, an HA tagged Tks5 PX domain will be introduced into cells with low levels of 
endogenous Tks5.  The lysates will then be run down a column with glutathione Sepharose 
beads coupled to GST fusion proteins of each Tks5 SH3 domain.  Bound proteins will be 
eluted, then separated using SDS-PAGE before being blotted for the HA-tagged PX domain.  
This will elucidate any binding between the PX domain and any of the SH3 domains of Tks5.  
A previous experiment has suggested binding between HA-PX and the third SH3 domain of 
Tks5, but this requires further substantiation (data not shown).   
The interaction between the PX and SH3 domains of Tks5 may also be investigated 
through co-immunoprecipitation.   A preliminary experiment of this nature has been 
conducted in which HEK293 cells were co-transfected with the Tks5 SH3 domain mutants 
and the isolated PX domain of Tks5 containing a GFP tag.  After a 48-hour incubation 
period, cells were lysed and co-immunoprecipitations were carried out using an antibody 
specific to the GFP epitope tag of the isolated PX domain of Tks5 and analyzing for Tks5 
using an antibody specific to the fourth SH3 domain of Tks5 (Figure 49).  Preliminary results 
point to a decrease in Tks5 domain interaction with the M3 Tks5 mutant construct, which is 
consistent with the modeled interaction of the PX domain with the third SH3 domain.  These 
results also appear to show an increase in Tks5 PX domain interaction with the M1 and M2 
Tks5 mutant constructs.  This is consistent with the suggested open conformation of these 
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constructs, allowing for accessibility of the third SH3 domain to bind to the PX domain of 
Tks5.  However, consistent expression levels of GFP-tagged PX domain and the Tks5 SH3 
domain mutant constructs were not obtained in this experiment, and thus the results overall 
remain promising, but ultimately inconclusive. 
 
 
 
Validation of Tks5 Closed Conformation through PX Domain Characterization 
Future experimentation will investigate the validity of the Tks5 masked conformation 
model.  The Tks5 SH3 domain mutants can be subjected to a phosphatidylinositol phosphate 
binding assay that tests for their ability to bind PI(3)P and PI(3,4)P2.  Presumably, those 
Figure 49. Co-immunoprecipitation of the isolated PX domain of Tks5 containing a GFP 
epitope tag and Tks5 SH3 domain mutant constructs in HEK293 cells.  Total cell lysates 
(input) were analyzed for the GFP tag on the isolated PX domain of Tks5 and for the Tks5 SH3 
domain mutant constructs by immunoblot analysis.  Lysates were also immunoprecipitated (IP) 
with a GFP antibody and analyzed for Tks5 PX-GFP and the Tks5 SH3 domain mutants by 
immunoblot analysis.  
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mutants containing an accessible PX domain (Tks5 M1, M2, and M3) should show stronger 
binding to these lipids. 
For identification of any binding that is occurring in vitro, the poly-proline motif in 
the PX domain of Tks5 could also be mutated to disrupt interactions with SH3 domains.  
This mutant construct of Tks5 can then be introduced into cells to study its effects such 
binding has on the activation of Tks5 and invadopodia formation and activity.  
Characterization of the binding properties and activation mechanisms behind the function of 
Tks5 can contribute to further understanding of cancer cell invasion leading to cancer 
metastasis as well as for the proposed roles of Tks5 in other diseases or in normal invasive 
cell types of the body.   
   
Investigating Tks5 Binding Partners using Tks5 SH3 Domain Mutants 
 Further studies may also elucidate the binding partners of Tks5 along with their 
locations of binding.  Binding partners have often been identified using isolated, GST-tagged 
SH3 domains, however this does not allow for how such binding might change in the context 
of the full length protein (Abram et al., 2003; Oikawa et al., 2008).  Using the Tks5 SH3 
domain mutants, it may be possible to further identify specific Tks5 binding partners.  In 
order to confirm the efficacy of this assay, an example of this was performed using 
dynamin2.  Dynamin2 is a protein shown to be involved in invadopodia formation through 
vesicle formation and actin filament organization regulation (Baldassarre et al., 2003).  Tks5 
has been suggested to bind to dynamin2 through its 1st and 2nd SH3 domains, which function 
together as a superSH3 domain, as well as through its 5th SH3 domain (Oikawa et al., 2008; 
Rufer et al., 2009).  Tks5 mutants were introduced into LNCaP cells alongside dynamin2.  
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After an incubation time of 48 hours, Tks5 was immunoprecipitated from the cells and 
analyzed for an interaction with dynamin2 through immunoblot analysis (Figure 50).  An 
interaction between Tks5 and dynamin2 was detected, and this interaction appeared to be 
diminished when the 2nd and 5th SH3 domains of Tks5 were disrupted.  This supports 
previous research done using GST-tagged SH3 domains demonstrating dynamin2 binding to 
the 1st and 2nd superSH3 and the 5th SH3 domains of Tks5 (Figure 8A).  However, a repeat of  
 
this experiment produced contradictory results, in which the M2 and M3 mutant Tks5 
constructs appeared to bind more strongly to dynamin2 (data not shown).  Clearly there are 
technical issues that need to be resolved in these immunoprecipitation assays before 
meaningful data can be obtained, but they nevertheless also point to the feasibility of 
identifying and characterizing the potentially important Tks5 conformations and associations 
likely to be necessary for invadopodia development as well.  In particular, if this assay is 
Figure 50. Co-immunoprecipitation of dynamin2 with Tks5 SH3 domain mutants in LNCaP 
cells.  Total cell lysates (Input) were analyzed for Tks5 and GFP-tagged dynamin2 by immunoblot 
(IB).  Lysates were also immunoprecipitated (IP) with a Tks5 antibody and analyzed for Tks5 and 
the GFP tag on dynamin2 by immunoblot as indicated.   
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successful, further study of any binding partners involved in Src endosomal trafficking could 
provide validation of the role of Tks5 in this specific aspect of invadopodia formation.   
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Supplementary Table SI. Tks5 associated proteinsa categorized by function.  
Categorical 
Function 
Putative 
Tks5 
Binding 
Partner 
Protein 
Classb 
Specific Functionb Association with 
Cancer 
Association 
with 
Invadopodia 
Target 
sequence 
or motifc 
Ref 
Actin-Related SH3P7 
(DBNL)d 
Adaptor Actin binding; 
antigen reception; 
JNK1 signaling; 
Rac activation; 
interacts with 
hematopoietic 
progenitor kinase 1a 
Upregulated in lung 
cancer; increased 
MELK expression in 
brain, breast, 
melanoma, colorectal 
cancers (DBNL is a 
MELK substrate) 
Localizes to 
podosomes 
and necessary 
for rosette 
formation; 
enhances 
membrane 
ruffling and 
invasiveness  
PxxP (2) 
Class III 
(1) 
1, 2, 
3 
Tropomyosin 
1 alpha-1 
chain splice 
isoforms 2 
and 3 
Cytoskeletal Stabilizing 
cytoskeletal actin 
filaments 
Cell transformation 
suppressor; 
downregulated in 
cancer 
Isoform 2 is 
found in and 
around 
invadopodia 
Class III 
(2) 
4, 5 
WIP-related 
protein 
(WIRE) 
Adaptor Relocalizes N-
WASp to actin; 
plays an active role 
in formation of cell 
surface protrusions 
downstream of 
activated PDGFB 
receptors.   
Cooperates with 
WASp and WASL.  
No strong evidence, 
possibly involved 
Localizes to 
invadopodia 
of MTLn3 and 
MDA-MB-
321 cells; 
localizes to 
podosomes of 
DCs, 
endothelial 
cells, and 
osteoclasts.  
PxxP (47) 
Class I (10) 
Class II (7) 
6 
Actin 
Polymerization 
Arp2/3 
complex 
Cytoskeletal Serve as nucleation 
sites for new actin 
Found in invasive 
cancer cells; 
overexpression in 
invasive breast, 
colorectal, lung 
cancers 
Necessary for 
formation 
PxxP (2) 
Class II (2) 
Class III 
(7) 
7, 8 
Cortactin* Cytoskeletal  Recruits Arp; 
stabilizes actin 
nucleation sites for 
actin branching 
Association with 
poor prognosis, 
overexpressed in 
numerous cancers 
Prominent 
component of 
invadopodia 
PxxP (2) 
Class I (1) 
Class III 
(5) 
9 
Drebrin Cytoskeletal Required for actin 
polymerization at 
immunological 
synapses 
Involved in 
tumorigenesis; 
overexpression in 
prostate cancer cells  
Necessary for 
podosome 
formation 
PxxP (15) 
Class I (2) 
Class III 
(1) 
10, 
11, 
12 
Cofilin-1 Cytoskeletal  Severs actin to 
generate new 
barbed ends for 
further actin growth 
Involved in 
metastasis; 
upregulated in 
prostate cancer 
Localizes at 
invadopodia, 
required for 
stability and 
ECM 
degradation 
 7, 
13, 
14 
Actin 
Regulation 
F-actin 
capping 
proteins 
alpha and 
beta 
Actin 
binding 
Binds ends of actin 
to block exchange 
of subunits 
Upregulation and 
downregulation has 
been shown in 
prostate cancers 
Localized at 
invadopodia 
Class III 
(1) 
15, 
16, 
17 
Tropomoduli
n-3 
Cytoskeletal Blocks elongation 
and 
depolymerization; 
regulates actin 
length  
  PxxP (1) 
 
 
Cytoskeleton 
component/relat
ed 
Beta-actin Cytoskeletal  Nonmuscle 
cytoskeletal actin 
Mutations are 
associated with 
tumorigenesis; 
upregulated in 
Found in 
invadopodia 
PxxP (1) 
Class III 
(2) 
18, 
19, 
20 
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prostate cancer in 
hypoxic conditions 
Gamma-
actin 
Cytoskeletal Globular actin; 
cytoplasmic; 
polymerization 
leads to F-actin 
strands 
Mutations associated 
with tumorigenesis 
 PxxP (1) 
Class III 
(2) 
18 
Kinesin-
related motor 
protein Eg5 
Cytoskeletal 
Motor 
Required for 
establishing a 
bipolar spindle; 
involved in 
centrosome 
migration 
Increased expression 
in actively 
proliferating cells; 
Cancer therapeutic 
target 
 PxxP (1) 
Class I (1) 
Class II (1) 
Class III 
(1) 
21, 
22 
Myosin II 
 
Mysoin light 
polypeptide 
6 
 
Myosin 
regulatory 
light chain 2 
Motor Motor proteins that 
move along actin 
filaments; required 
for cytoskeleton 
organization; 
Regulatory myosins 
regulate contractile 
activity 
Role in metastasis Present in 
ring-like 
structures and 
around a 
subset of 
invadopodia  
PxxP (1) 
Class II (1) 
Class III 
(9) 
23, 
24 
Tubulin Cytoskeletal Makes up 
microtubules 
Cancer therapeutic 
target 
Required for 
elongation of 
invadopodia 
Class III 
(4) 
25, 
26, 
27 
Vimentin Cytoskeletal Intermediate 
filament specific to 
mesenchymal tissue 
Associated with 
EMT and loss of 
adhesions; 
overexpression 
associated with 
invasiveness 
Required for 
elongation of 
invadopodia 
Class III 
(1) 
26, 
28 
Nucleotide 
synthesis 
C1-
tetrahydrofol
ate synthase 
Enzyme De novo synthesis 
of purines and 
thymidylate; 
regeneration of 
methionine 
Upregulated in colon 
cancer; potential 
cancer therapeutic 
target 
 PxxP (7) 
Class I (4) 
Class II (3) 
Class III 
(2) 
29, 
12 
Inosine-5’-
monophosph
ate 
dehydrogena
se 2 
Enzyme Catalyzes first rate-
limiting step in 
guanine nucleotides 
Attractive target for 
cancer; upregulated 
in cancers 
 Class III 
(3) 
30, 
31 
Translation 
machinery 
Ribosomal 
subunits: 
 
40S S3 
 
40S S11 
 
40S S13 
 
40S S16 
 
40S S18 
 
60S L11 
 
60S L12 
 
60S L23 
 
60S L26 
Ribosomal Creates ribosomes 
which catalyze 
protein synthesis 
Some ribosomal 
subunits have been 
shown to be 
overexpressed in 
cancer; S16 
upregulated in 
prostate cancer 
 S3: 
PxxP (5) 
Class I (1) 
 
S11: 
Class III 
(2) 
 
S13:  
PxxP (1) 
Class III 
(4) 
 
S16: 
Class III 
(1) 
 
S18:  
Class III 
(2) 
 
L11: 
Class III 
(5) 
 
L12: 
Class III 
(1) 
32, 
33 
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L23:  
Class III 
(1) 
 
L26:  
Class III 
(1) 
Elongation 
factor 1-
alpha 1 
Translation Recruits tRNA to A 
site 
Overexpressed in 
cancer; oncogene; 
has potential as a 
prostate cancer 
marker 
 PxxP (2) 
Class III 
(1) 
32, 
34, 
35 
Elongation 
factor 2 
Translation Ribosomal 
translocation of 
mRNA from A site 
to P site 
Expression and 
activity increased in 
cancer cells 
Found in 
invadopodia  
PxxP (2) 
Class III 
(4) 
36, 
37, 
20 
Eukaryotic 
initiation 
factor 4A-I 
Translation; 
Helicase 
Responsible for 
RNA helicase 
activity of 
translation initiation 
complex; involved 
in cap recognition 
and required for 
mRNA binding to 
ribosome 
Well established 
oncogene 
 Class III 
(1) 
38, 
39 
Eukaryotic 
translation 
initiation 
factor 3 
subunit 2 
Translation  Cap independent 
translation 
initiation; associates 
with ribosomal 40S 
subunit and 
promotes binding of 
methionyl-tRNAi 
and mRNA 
Overexpressed in 
colon cancer 
 Class III 
(1) 
40, 
41 
Methionyl-
tRNA 
synthetase 
Enzyme Covalently links 
methionine with 
cognate tRNA 
Overexpression of 
substrate tRNA;met 
can cause 
transformation; 
overexpressed in 
cancer 
 PxxP (5) 
Class I (1) 
Class III 
(3) 
42, 
43 
RNA binding 
proteins 
Dead box 
protein 3 
Enzyme RNA Helicase 
involved in RNA 
metabolism and 
gene expression 
Overexpressed in 
breast cancer; tumor 
suppressor in 
hepatocellular 
carcinoma 
 PxxP (1) 
Class III 
(2) 
44, 
45 
hnRNP K RNA 
splicing/bind
ing 
Complexes with 
heterogeneous 
nuclear RNA (Pre-
mRNAs) 
Increased expression 
and nuclear shift in 
cancer 
Localizes to 
macrophage 
podosomes 
and 
invadopodia  
PxxP (9) 
Class I (5) 
Class II (3) 
46, 
47, 
20, 
48 
Transcription 
machinery 
Methylosom
e protein 50 
 
Adaptor 
 
Interaction with 
spliceosome 
proteins inhibits 
splicosome 
assembly 
Involved in 
tumorigenesis 
 PxxP (3) 
Class III 
(1) 
 
49 
Methylosom
e subunit pI 
Cln 
Channel Regulates 
spliceosome 
assembly  
Involved in 
tumorigenesis 
 PxxP (1) 49 
Ras-GTPase-
activating 
protein 
binding 
protein 1 
Enzyme; 
Adaptor 
DNA unwinding 
enzyme; involved in 
MAPK signaling; 
member of hnRNA 
binding proteins 
Highly overexpressed 
in various cancers 
and closely 
associated with 
invasion and 
metastasis  
 PxxP (2) 
Class I (1) 
Class II (1) 
50 
Small 
nuclear 
ribonucleopr
otein 
associated 
RNA 
binding 
Component of 
spliceosome 
Alternative splicing 
can lead to cancer; 
increased splicing 
rates in cancer 
(possible therapeutic 
 PxxP (10) 
Class I (5) 
Class III 
(4) 
51 
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proteins B 
and B’ 
target) 
Protein 
arginine N-
methyltransf
erase 5 
 
SKB1 
protein 
arginine N-
methyltransf
erase 
Enzyme Methylates histones 
H2A and H4 
(histones involved 
in transcriptional 
repression) 
Components of 
methylosome 
Oncogene; 
overexpressed in 
cancer  
 PxxP (2) 
Class III 
(6) 
49, 
52, 
53, 
54 
RuvB-like 1 
(Pontin) 
 
RuvB-like 2 
(Reptin) 
Enzyme Helicase activity, 
activation of 
acetylation of H2A 
and H4  
Increased expression 
in cancer; promotes 
increased 
proliferation  
 Pontin: 
PxxP (1) 
Class I (1) 
 
Reptin: 
PxxP (1) 
Class III 
(2) 
55 
Chaperone 
proteins 
GRP 78 
glucose-
regulated 
protein 
precursor 
Chaperone Precursor to Hsp Helps with 
adaptation to stress in 
tumor 
microenvironment; 
increased expression 
in cancers 
 PxxP (1) 
Class III 
(1) 
56 
Hsp60 Chaperone Prevents protein 
aggregation; helps 
protein folding 
Enhanced expression 
in breast carcinoma, 
prostate cancer, and 
myeloid leukemia 
 Class III 
(2) 
57, 
58 
Hsp70.1; 
70.8 
Chaperone Resistance to cell 
death, prevents 
protein aggregation, 
helps protein 
folding 
Expression enhanced 
after transformation; 
increased expression 
in LNCaPs  
Hsp 70 protein 
8 isoforma 1 
variant found 
in 
invadopodia  
PxxP (2) 
Class III 
(9) 
57, 
58, 
20 
Hsp90-
alpha4; beta 
Chaperone Forms stable 
complexes with 
actin to protect 
filaments; prevents 
protein aggregation; 
helps protein 
stabilization and 
trafficking; 
facilitates protein 
activation 
Potential cancer 
target 
Hsp90-Beta 
found in 
invadopodia 
PxxP (1) 
Class III 
(11) 
57, 
59, 
20 
Stress-70 
protein 
Chaperone Implicated in 
control of cell 
proliferation and 
aging; may act as 
chaperone 
Up-regulated in 
cancers 
  60, 
61 
T-complex 
protein 1: 
beta, delta, 
theta, and 
zeta subunits 
Chaperone Molecular 
chaperone; folds 
polypeptides 
including actin and 
tubulin 
 T-complex 
protein 1 
isoform a 
found in 
invadopodia  
PxxP (2) 
Class III 
(8) 
20 
Mitosis related NDR1 
protein 
kinase 
Enzyme Regulates proper 
cell function related 
to development, 
growth and mitosis; 
required for 
centriole 
duplication 
Downregulated in 
tubular carcinoma 
and some prostate 
cancers; appears to 
be a tumor 
suppressor but some 
upregulation in 
cancer suggests 
proto-oncogenic 
activity 
 PxxP (1) 
Class III 
(2) 
62, 
63 
Protein 
phosphatase 
2C beta 
Enzyme Kinase inhibitor 
including oncogenic 
signaling proteins 
Associated with 
cancer related 
biological processes; 
increased expression 
 PxxP (3) 
Class III 
(1) 
64 
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in cancers; oncogene 
Ras activation 14-3-3 beta 
 
14-3-3 
gamma 
 
14-3-3 theta 
 
14-3-3 zeta 
Adaptor  Mediates signal 
transduction by 
binding 
phosphoserine-
containing proteins; 
regulates Ras 
effectors 
Cancer therapy 
target; regulates 
important cancer 
processes 
(14-3-3 
epsilon is 
involved with 
invadopodia 
and cofilin) 
Beta: 
PxxP (1) 
Class II (1) 
Class III 
(1) 
 
Gamma: 
PxxP (1) 
Class II (1) 
 
Theta: 
PxxP (1) 
Class II (1) 
 
Zeta: 
PxxP (1) 
Class II (1) 
 
65 
CrkLd Adaptor Activates Ras and 
JUN; cytoskeleton 
regulator; substrate 
of Bcr-Abl 
Oncogene; increased 
expression found in 
some cancers 
Abl kinases 
required for 
invadopodia 
formation 
PxxP (4) 
Class I (1) 
Class III 
(1) 
66, 
67, 
68 
Nck1 
 
Nck2 
Adaptor Transducing signals 
from RTKs to 
downstreams like 
RAS; coordinates 
actin cytoskeleton 
remodeling 
Overexpression in 
cancer; Nck1 
overexpression 
transforms fibroblasts 
Nck1 localizes 
to 
invadopodia, 
important for 
formation and 
function; 
Nck2 links 
Tks5 to 
invadopodia 
regulation 
Nck1: 
PxxP (2) 
Class I (2) 
69, 
70, 
71 
Grb2 Adaptor Signal transduction 
and cell 
communication; 
links EGFR to 
activation of Ras, 
Erk1/2 
Over expression in 
cancers 
Does not 
localize to 
invadopodia, 
does localize 
to degradative 
structures 
formed by 
transformed 
fibroblasts 
PxxP (1) 69, 
72, 
73 
Remaining 5’-AMP 
activated 
protein 
kinase  
 
(catalytic 
alpha-1 
chain; 
gamma-1 
subunit) 
Enzyme Cellular energy 
homeostasis; 
regulator of cellular 
polarity through 
actin cytoskeleton 
remodeling; 
activated by 
environmental 
stress 
Activated to treat 
cancer; some 
enzymes 
overexpressed in 
cancer are inhibited 
by AMPK  
Activation 
leads to 
decrease in 
fatty acid 
synthesis, 
leading to a 
decrease in 
invadopodia 
PxxP (2) 
Class III 
(6) 
 
74, 
75, 
76 
Creatine 
kinase B-
type 
Enzyme Catalyzes 
conversion of 
creatine to 
phosphocreatine 
Levels increased in 
some cancers; 
downregulated in 
LNCaP and PC3 cell 
lines 
 PxxP (2) 
Class III 
(1) 
77, 
78, 
12 
D-3-
phosphoglyc
erate 
dehydrogena
se 
Enzyme Catalyzes 3-
phosphoglycerate 
into 3-
phosphohydroxypyr
uvate 
Increased activity in 
cancer 
 PxxP (3) 
Class II (1) 
79 
Mouse Tks5 Adaptor Scaffold protein 
involved in 
invadopodia and 
podosome 
formation 
Increased expression 
in cancers 
Necessary for 
invadopodia 
structure and 
function 
PxxP (16) 
Class I (5) 
Class II (6) 
Class III 
(3) 
80, 
81, 
82 
Peroxiredoxi
n 1 
Enzyme Antioxidant Increased expression 
in cancer; expression 
Possibly needs 
to be 
 83, 
84, 
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correlated with 
cancer progression 
and growth 
inactivated for 
invadopodia 
formation 
85 
aList of binding partners based on proteins identified as associating with FLAG-Tks5 constructs (Stylli et al., 2009; Table S1).  
bInformation found using PhosphoSite (http://www.phosphosite.org/) and UniProt Knowledgebase  
(http://www.uniport.org/). 
cTarget sequences and motifs are based on those previously described as being general consensus for SH3 binding specificity.  
(Carducci, et al., 2012).   Quantity of each motif found is displayed in parentheses next to motif type.  Motif searches were carried out 
using ScanProsite (http://www.prosite.expasy.org/scanprosite/).  Class I: (R/K)xxPxxP or (R/K)xPxxP; Class II: PxxPx(R/K); Class III: 
RxxK 
dCould not confirm stable interaction with Tks5 
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